Patent Application
20220056484
A Sequence Listing is incorporated herein by reference as part of the disclosure. The sequence listing has been submitted as a text file named “56486_Seqlisting”, which was created on Apr. 8, 2021, and is 49,234 bytes in size.
The present invention relates to methods for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells. The present invention also relates to a population of genome edited cells produced by the method, pharmaceutical compositions comprising the population of genome edited cells, use of the population of genome edited cells for therapy (such as gene therapy, hematopoietic stem cell transplantations, cancer treatments and tissue repair), and methods for the treatment or prevention of disorders, such as X-linked SCID and skin diseases or retinal diseases, comprising the step of administering a population of genome edited cells.
Hematopoietic stem cell (HSC) gene therapy has provided substantial therapeutic benefit in patients affected by several hematological and non-hematological diseases. Yet, the use of semi-randomly integrating vectors still poses the risk of insertional mutagenesis and non-physiological transgene expression. Therefore, the scope of HSC genetic engineering has broadened from gene replacement to targeted genome editing, which relies on the use of artificial nucleases for precise modification of endogenous genes. Gene editing in primitive hematopoietic stem/progenitor cells (HSPCs) has remained elusive for years. Indeed, the induction of DNA double strand break (DSB) in these cells may trigger apoptosis, differentiation or senescence and its repair may proceed by non-homologous end joining (NHEJ) rather than homology-directed DNA repair (HDR), which requires upregulation of the relevant protein machinery and progression of the targeted cell through the cell cycle.
Remarkable advances in ex vivo HSC culturing, nuclease design and gene transfer technologies has allowed these barriers to be partially overcome and has provided clear evidence of targeted genome editing in human HSPCs capable of long-term multi-lineage reconstitution in immunodeficient NSG mice (Genovese et al., 2014). More recently, further optimizations of gene editing reagents and procedures significantly improved gene targeting efficiency in primitive HSPCs, achieving on average 10-20% of gene marking in long-term engrafting HSPCs (De Ravin et al., 2017; Dever et al., 2016; Wang et al., 2015). These levels of gene correction have been predicted to be safe and effective for the treatment of some diseases, such as in the case of X-linked Severe Combined Immunodeficiency (SCID-X1), in which the edited progeny would have the benefit of selective advantage over non-edited counterpart (Schiroli et al., 2017).
However, there are several challenges that HSC gene editing faces before it becomes suitable for broader clinical application. In particular, it is crucial to improve the efficiency of gene editing in more primitive HSPCs as well as the yield of edited HSCs. Although further improvements in gene editing protocols might enhance gene targeting efficiency, in vitro selection of corrected HSPCs before administration could be a valuable strategy to obtain a pure population of edited cells. Selection of the gene edited cells is difficult when the level of gene correction is not sufficient to achieve the reversion of a pathological process. Further, it may be difficult to directly select for the intended editing as the corrected gene may not provide a growth advantage (such as occurs in chronic granulomatous disease, thalassemias, RAG1 deficiency, etc). In addition, the gene edited cells may not be amenable to selection because of intracellular localization of its relative protein product or the protein may not even be expressed in HSPCs.
To overcome these hurdles, gene editing might be coupled with constitutive expression of selectable markers, such as fluorescent proteins, which are amenable for FACS-sorting, or drug-resistance proteins, followed by drug treatment to mediate selection. However, constitutive expression of a reporter gene can be immunogenic or detrimental to long term cell viability, thus potentially leading to the loss of the modified cells. Finally, these systems will lead to the selection of both in situ and off-site targeted insertions, thus jeopardizing the therapeutic and safety outcomes.
The breakthrough of engineered transcriptional transactivators (ETTs) has opened new possibilities to precisely regulate the expression of an intended gene. In particular, TALE and CRISPR/Cas systems have been engineered by fusing the DNA binding domain (DBD) or catalytically inactive Cas9 (dCas9), respectively, with single or multiple transcriptional activator domains (such as VP64 and VPR) (Chavez et al., 2015).
Guo et al (2017, Protein Cell 8(5):379-393) discuss a system to upregulate endogenous genes in human pluripotent stem cells (HPSCs). Guo et al (2017) disclose the insertion of a doxycycline (Dox) inducible dCas9-VP64-p65-Rta and a Tet transactivator expression cassette into two alleles of the AAVS1 locus and that the level of dCas9-VPR can be controlled precisely and reversibly by the addition and withdrawal of Dox.
Dever et al (2016, Nature 539(7629): 384-389) discuss homologous recombination at the HBB gene in human stem cells (HSC) by using the combination of Cas9 ribonucleoproteins and recombinant AAV6 homologous recombination donor delivery. Dever et al (2016) disclose AAV vector plasmids comprising tNGFR. Dever et al (2016) discuss using tNGFR as a marker to enrich HBB targeted HSPCs and anti-NGFR magnetic-bead separation.
Bak et al (2018, Nat Protoc 13(2):358-376) discuss the use of CRISPR/Cas9 technology and recombinant AAV6 homologous donor delivery for editing human hematopoietic stem cells by homologous recombination. Bak et al (2018) disclose reporter genes such as GFP or truncated growth factor receptor (tNGFR). Bak et al (2018) discuss flow cytometry to enrich for cells with targeted integration.
US2015/0191744 discusses methods for modifying the transcriptional regulation of stem or progenitor cells using a lentiviral vector encoding a nuclease deficient Cas9 effector domain fusion protein and a lentiviral vector comprising at least one sgRNA gene complementary to a genomic target. US2015/0191744 discloses a Cas9-fluorescent protein fusion protein.
The present inventors have developed a platform to achieve gene editing and enrichment of edited cells before in vivo administration, thus increasing the efficacy of gene therapy, and potentially expanding its application to a wide spectrum of genetic diseases, including those in which no proliferative growth advantage is conferred to corrected cells.
The present inventors have developed methods for selecting edited cells that couple particular donor DNA vector designs (the first component) with the use of engineered transcriptional transactivators (ETTs) (the second component) combined with a nuclease system (the third component) to drive the selection of edited cells. The present inventors have exploited transient expression of neutral genes as selectable markers, such as the cell-surface-expressed mutated Low-affinity Nerve Growth Factor Receptor (ΔLNGFR), upon on-site recombination, and specific selection of edited cells.
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
(a) introducing into a cell (i.e. the starting cell) or a population of cells (i.e. a starting population of cells) at least one first component, at least one second component and at least one third component; and
(b) selecting the genome edited cells which transiently express or transiently upregulate a nucleotide sequence encoding a selector;
wherein the first component is a donor reporter cassette comprising the nucleotide sequence encoding the selector and a nucleotide sequence of interest (NOI);
wherein the second component is an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide; wherein the ETT polypeptide comprises a DNA binding domain (DBD) and at least one transcription activator (TA) domain;
wherein the third component is a nuclease system comprising a genome targeted nuclease and, optionally, a guide RNA (gRNA) comprising at least one targeted genomic sequence;
wherein the ETT polypeptide is transiently present in the cell or population of cells or the nucleotide sequence encoding the ETT polypeptide is transiently expressed in the cell or population of cells; and
wherein the presence of the nuclease system in the cell or the population of cells enables the insertion of the nucleotide sequence encoding the selector (and, optionally, a minimal promoter) and the NOI into a target locus and wherein the transient presence of the ETT polypeptide or the transient expression of the nucleotide sequence encoding the ETT polypeptide enables transient expression or transient upregulation of the inserted nucleotide sequence encoding the selector.
Transient expression or transient upregulation of a nucleotide sequence encoding a selector enables the specific selection of cells in which the nucleotide sequence encoding the selector and a nucleotide sequence of interest (NOI) has been inserted into the target locus from those cells in which the nucleotide sequence encoding the selector and a nucleotide sequence of interest (NOI) have not been inserted into the target locus.
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
The present invention provides a method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
Without wishing to be bound by theory, the transient presence of the modulator in the cell or population of cells may occur by the addition of the modulator to the media followed by subsequent washing of the cell or population of cells.
In one embodiment, (herein referred to as Selection by Means of Artificial Transactivators [SMArT]), the first component comprises a donor reporter cassette, in which the expression of a selector (such as the mutated Low-affinity Nerve Growth Factor Receptor [ΔLNGFR]) is driven by a minimal promoter (such as cytomegalovirus [CMV] or synthetic promoter [T6-SK] (Loew, Heinz, Hampf, Bujard, & Gossen, 2010)), that should putatively limit basal expression of the selector. The first component comprises homologous arms (HAs) comprising nucleotide sequences homologous to the target locus, these HAs enable the donor reporter cassette to be inserted into the target locus by homology-driven repair (HDR). The donor reporter cassette further comprises a NOI operably linked to a promoter. ETT binding sites are outside the homology arms and upstream of the minimal promoter. Insulator elements might be also present in the cassette in order to limit the possible enhancer activity of the fully efficient promoter on the minimal promoter. In this case, insulator elements might be derived from CTCF-dependent or independent binding sites (Phillips-Cremins & Corces, 2013) (
In one embodiment, (herein referred to as Selection by Means of Artificial Transactivators [SMArT] gene correction), the first component comprises a donor reporter cassette, in which the expression of a selector (such as the mutated Low-affinity Nerve Growth Factor Receptor [ΔLNGFR]) is driven by a minimal promoter (such as cytomegalovirus [CMV] or synthetic promoter [T6-SK] (Loew, Heinz, Hampf, Bujard, & Gossen, 2010)), that should putatively limit basal expression of the selector. The first component comprises homologous arms (HAs) comprising nucleotide sequences homologous to the target locus, these HAs enable the donor reporter cassette to be inserted into the target locus by homology-driven repair (HDR). The donor reporter cassette further comprises a NOI. (Optionally, the cassette further comprises a splicing acceptor site and/or a nucleotide sequence encoding a self-cleaving 2A peptide or, alternatively, an internal ribosome entry site (IRES) element.) The insertion of the donor reporter cassette into the target locus corrects a genetic defect and/or introduces a new function into the endogenous gene. ETT binding sites are outside the homology arms and downstream of the minimal promoter. Insulator elements might be also present in the construct in order to limit the possible enhancer activity of the fully efficient promoter on the minimal promoter. In this case, insulator elements might be derived from CTCF-dependent or independent binding sites (Phillips-Cremins & Corces, 2013) (
In another embodiment, (herein referred to as Selection by Means of Artificial Transactivation of Endogenous Receptors [SMArTER]) the donor reporter cassette comprises: (i) a nucleotide sequence of interest; ii) optionally a splicing acceptor site and/or a nucleotide sequence encoding a self-cleaving 2A peptide or, alternatively, an internal ribosome entry site (IRES) element; iii) the cDNA encoding for the selector protein (such as ΔLNGFR), optionally the nucleotide sequence encoding the selector is operably linked to a minimal promoter; and iv) homology arms (HAs) for the intended target site(s). ETT binding sites are situated close to the promoter of the endogenous gene in order to transiently boost (i.e. transiently upregulate) the expression of the selector (and the edited gene) upon targeted integration (
In another embodiment, (herein referred to as Selection by Means of Artificial Transactivation with Doxycycline regulation [SMArT-D]) the first component comprises a donor reporter cassette, in which the expression of a selector (such as GFP) is driven by a minimal promoter (such as synthetic promoter [T6-SK] (Loew, Heinz, Hampf, Bujard, & Gossen, 2010)), that should putatively limit basal expression of the selector, wherein the minimal promoter is operably linked to a regulatory element (such as a tetracycline operator (TetO) sequence). The regulatory element is typically upstream of the minimal promoter. ETT binding sites are within the regulatory element. Without wishing to be bound by theory, in the Tet-Off system, the ETT binds to the regulatory element and activates the minimal promoter when the selector is inserted into the target locus; the binding of a modulator (such as tetracycline or deoxycycline) prevents the binding of the ETT to the regulatory element when a donor reporter cassette has not been inserted into the target locus. Without wishing to be bound by theory, in the Tet-On system, the ETT binds to the regulatory element and activates the minimal promoter when the selector is inserted into the target locus and when a modulator (such as tetracycline or deoxycycline) is present; the binding of a modulator (such as tetracycline or deoxycycline) enables the binding of the ETT to the regulatory element when a donor reporter cassette has been inserted into the target locus. The first component further comprises homologous arms (HAs) comprising nucleotide sequences homologous to the target locus, these HAs enable the donor reporter cassette to be inserted into the target locus by homology-driven repair (HDR). Insulator elements might be also present in the cassette in order to limit the possible enhancer activity of the fully efficient promoter on the minimal promoter. In this case, insulator elements might be derived from CTCF-dependent or independent binding sites (Phillips-Cremins & Corces, 2013) (
In one aspect, the present invention provides a population of genome edited cells produced by the method according to the present invention.
The population of genome edited cells produced by the method according to the present invention comprise the nucleotide sequence encoding the selector. The nucleotide sequence encoding the selector is transiently expressed such that the nucleotide sequence encoding the selector is no longer expressed after the cells have been selected.
The population of genome edited cells produced by the method according to the present invention is enriched for cells which are capable of expressing the nucleotide of interest (NOI).
In a further aspect, the present invention provides a pharmaceutical composition comprising the population of genome edited cells according to the present invention.
In a broad aspect, the present invention provides a population of genome edited cells according to the present invention for use in therapy.
In another aspect, the present invention provides a population of genome edited cells according to the present invention for use in gene therapy, hematopoietic stem cell transplantation, cancer treatment and/or tissue repair.
The present invention provides, in a further aspect, a population of genome edited cells according to the present invention for use in the treatment or prevention of X-linked Severe Combined Immunodeficiency (SCID-X1), a skin disease and/or a retinal disease.
In a further aspect, the present invention provides a population of genome edited cells according to the present invention for use in the treatment or prevention of a monogeneic disorder such as epidermolysis bullosa and/or retinitis pigmentosa and/or Hyper-IgM (HIGM) syndrome.
In a further aspect, the present invention provides a population of genome edited cells according to the present invention for use in the treatment or prevention of Hyper-IgM (HIGM) syndrome.
In a broad aspect, the present invention provides use of a population of genome edited cells according to the present invention for therapy.
The present invention provides in another aspect, use of a population of genome edited cells according to the present invention for gene therapy, hematopoietic stem cell transplantation, cancer treatment and/or tissue repair.
In a further aspect, the present invention provides use of a population of genome edited cells according to the present invention for the manufacture of a medicament for the treatment or prevention of X-linked SCID, a skin disease and/or a retinal disease.
In a further aspect, the present invention provides use of a population of genome edited cells according to the present invention for the manufacture of a medicament for the treatment or prevention of a monogeneic disorder such as epidermolysis bullosa and/or retinitis pigmentosa and/or Hyper-IgM (HIGM) syndrome.
In a further aspect, the present invention provides use of a population of genome edited cells according to the present invention for the manufacture of a medicament for the treatment or prevention of Hyper-IgM (HIGM) syndrome,
In a broad aspect, the present invention provides a method of therapy comprising the step of administering a population of genome edited cells according to the present invention to a subject.
In another aspect, the present invention provides a method of gene therapy, hematopoietic stem cell transplantation, cancer treatment and/or tissue repair comprising the step of administering a population of genome edited cells according to the present invention to a subject.
The present invention provides, in another aspect, a method for the treatment or prevention of X-linked SCID, a skin disease and/or a retinal disease comprising the step of administering a population of genome edited cells according to the present invention to a subject wherein the subject has X-linked SCID, a skin disease and/or a retinal disease.
The present invention provides, in another aspect, a method for the treatment or prevention of a monogeneic disorder such as epidermolysis bullosa and/or retinitis pigmentosa and/or Hyper-IgM (HIGM) syndrome comprising the step of administering a population of genome edited cells according to the present invention to a subject wherein the subject has a mongeneic disorder.
The present invention provides, in another aspect, a method for the treatment or prevention of Hyper-IgM (HIGM) syndrome comprising the step of administering a population of genome edited cells according to the present invention to a subject wherein the subject has Hyper-IgM (HIGM) syndrome.
The terms “comprising”, “comprises” and “comprised of” as used herein are synonymous with “including” or “includes”; or “containing” or “contains”, and are inclusive or open-ended and do not exclude additional, non-recited members, elements or steps. The terms “comprising”, “comprises” and “comprised of” also include the term “consisting of”.
Genome Edited Cells
The term “genome edited cells” refers to a type of genetic engineering in which a nucleotide sequence is inserted, deleted, disrupted or replaced in the genome of a cell. The terms “genome edited cells”, “edited cells”, “gene edited cells”, “targeted gene therapy” and “gene editing” may be used interchangeably herein. Gene editing may be achieved using engineered nucleases (which herein may be referred to as the third component), which may be targeted to a desired site in a polynucleotide. Such nucleases may create site-specific double-strand breaks at desired locations, which may then be repaired through non-homologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations. Such nucleases may be delivered to a target cell using viral vectors. Gene editing enlists the cell's own repair pathways to correct, disrupt, or add a target locus. For instance, in gene editing to correct a sequence, a template sequence for homology repair is provided and the cell's own repair pathways erase the mutation and replace it with the correct sequence. For instance, in gene editing to add a sequence, a template sequence for homology repair is provided and the cell's own repair pathways integrate a cassette allowing expression of a NOI in a site-specific manner. For instance, in gene editing to disrupt a gene a template sequence for homology repair is provided and the cell's own repair pathways mutate, insert or gene delete to disable the function of a gene.
Examples of suitable nucleases known in the art include zinc finger nucleases (ZFNs), transcription activator like effector nucleases (TALENs), the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas system and the CRISPR/Cpf system (Gaj, T. et al. (2013) Trends Biotechnol. 31: 397-405; Sander, J. D. et al. (2014) Nat. Biotechnol. 32: 347-55).
Meganucleases (Silve, G. et al. (2011) Cur. Gene Ther. 11: 11-27) may also be employed as suitable nucleases for gene editing.
The CRISPR/Cas system is an RNA-guided DNA binding system (van der Oost et al. (2014) Nat. Rev. Microbiol. 12: 479-92), wherein the guide RNA (gRNA) may be selected to enable a Cas domain (such as Cas9) or a Cpf domain (such as Cpf 1) to be targeted to a specific sequence. Methods for the design of gRNAs are known in the art. Furthermore, fully orthogonal Cas9 proteins, as well as Cas9/gRNA ribonucleoprotein complexes and modifications of the gRNA structure/composition to bind different proteins, have been recently developed to simultaneously and directionally target different effector domains to desired genomic sites of the cells (Esvelt et al. (2013) Nat. Methods 10: 1116-21; Zetsche, B. et al. (2015) Cell pii: S0092-8674(15)01200-3; Dahlman, J. E. et al. (2015) Nat. Biotechnol. 2015 Oct. 5. doi: 10.1038/nbt.3390. [Epub ahead of print]; Zalatan, J. G. et al. (2015) Cell 160: 339-50; Paix, A. et al. (2015) Genetics 201: 47-54), and are suitable for use herein.
By “enrichment” of a population of cells for genome edited cells it is to be understood that the proportion (or concentration) of genome edited cells is increased within the population of cells. The concentration of other types of cells may be concomitantly reduced.
In some embodiments, the population of cells is an isolated population of cells. The term “isolated population” of cells as used herein may refer to the population of cells having been previously removed from the body. An isolated population of cells may be cultured and manipulated ex vivo or in vitro using standard techniques known in the art. An isolated population of cells may later be reintroduced into a subject. Said subject may be the same subject from which the cells were originally isolated or a different subject.
A population of cells may be enriched or purified selectively for cells that exhibit a specific phenotype or characteristic, and from other cells which do not exhibit that phenotype or characteristic, or exhibit it to a lesser degree. For example, a population of cells that expresses a specific selector (such as ΔLNGFR, NGFR, truncated NGFR, MGMT, CD19, EGFR, c-Kit, CXCR4, CXCR4 WHIM, CD47 and eGFP) may be purified from a starting population of cells. Alternatively, or in addition, a population of cells that does not express another selector may be purified.
Enrichment or purification may result in the population of cells being substantially pure of other types of cell.
Enriching or purifying for cells or a population of cells expressing a specific selector (e.g. ΔLNGFR, NGFR, truncated NGFR, MGMT, CD19, EGFR, c-Kit, CXCR4, CXCR4 WHIM, CD47 and eGFP) may be achieved by using an agent that binds to that marker, preferably substantially specifically to that marker. For example, a population of genome edited cells could be marked by antibodies, proteins or aptamers that are specific for the marker and that are conjugated, directly or indirectly, with a fluorescent dye or paramagnetic beads. Thus, selection of the marked cells could be performed by fluorescence-activated cell sorting, magnetic columns, affinity tag purification or microscopy-based techniques.
In some embodiments, the nucleotide sequence encodes a selector selected from the group consisting of ΔLNGFR, NGFR, MGMT, CD19, EGFR, c-Kit, CXCR4, CXCR4 WHIM, CD47 and eGFP.
Transient Expression or Transient Upregulation
When the second component is an ETT polypeptide, the ETT polypeptide is transiently present in the cell or population of cells. Without wishing to be bound by theory, the transient presence of the ETT polypeptide occurs due to intracellular degradation of this second component.
When the second component is a nucleotide sequence encoding the ETT polypeptide, the nucleotide sequence is transiently expressed in the cell or population of cells. Without wishing to be bound by theory, the transient expression of the nucleotide sequence encoding the ETT polypeptide occurs due to intracellular degradation of this second component. In addition, the transient expression of the nucleotide sequence encoding the ETT polypeptide results in the short term production of the ETT polypeptide. In turn, the ETT polypeptide is only transiently present in the cell or population of cells as the ETT polypeptide undergoes intracellular degradation.
Binding sites for the ETT polypeptide (ETT binding sites) are operably linked to the target locus in the genome of the cell. In some embodiments, the at least one ETT binding site is upstream of the target locus. In other embodiments the at least one ETT binding sites are downstream of the target locus. The presence of the ETT binding site enables the expression of the nucleotide sequence encoding the selector inserted at the target locus when the ETT polypeptide is present in the cell. Without wishing to be bound by theory, in genome edited cells, ETT bound to the ETT binding site can act on an endogenous promoter operably linked to the target locus or an exogenous promoter (such as a minimal promoter) operably linked to the nucleotide sequence encoding the selector inserted into the target locus. Expression of the nucleotide sequence encoding the selector can be modulated independently from expression of the NOI in genome edited cells unless the nucleotide sequence encoding the selector and the NOI are the same sequence.
The transient presence of the ETT polypeptide in a cell or population of cells enables the transient expression or the transient upregulation of the inserted nucleotide sequence encoding the selector when the nucleotide sequence encoding the selector is inserted into the target locus (this may be referred to as “on-site” insertion). If the nucleotide sequence encoding the selector is inserted into a non-target locus (this may be referred to as “off-site” insertion) then the nucleotide sequence encoding the selector is not expressed.
The transient expression of the nucleotide sequence encoding the ETT polypeptide enables the transient expression or the transient upregulation of the inserted nucleotide sequence encoding the selector when the nucleotide sequence encoding the selector is inserted into the target locus (this may be referred to as “on-site” insertion). If the nucleotide sequence encoding the selector is inserted into a non-target locus (this may be referred to as “off-site” insertion) then the nucleotide sequence encoding the selector is not expressed.
In some embodiments, the transient expression or the transient upregulation of the inserted nucleotide sequence encoding the selector requires the presence of a modulator in the cell. In other embodiments, the transient expression or the transient upregulation of the inserted nucleotide sequence encoding the selector does not require the presence of a modulator in the cell.
The term “transiently express a nucleotide sequence encoding a selector” as used herein refers to a temporary expression of the nucleotide sequence encoding the selector. The transient expression of the selector enables the selection of the genome edited cells during this period of selector expression.
The term “transiently upregulate a nucleotide sequence encoding a selector” as used herein refers to a temporary increase in the expression of the nucleotide sequence encoding the selector. The transient upregulation of the selector enables the selection of the genome edited cells during this period of selector upregulated expression.
The upregulation of a selector refers to an increase in the level of expression of the selector within the population of cells that contain targeted integration of the NOI in comparison to the population of cells that does not contain integration of NOI in the target site under otherwise identical conditions.
Advantageously, the genome editing method of the present invention results in the expression or the upregulation of the selector for a short period of time. During this period of time, the genome edited cells can be selected.
For gene therapy, for instance, advantageously the genome edited cells do not express the selector or do not have upregulated expression of the selector when the cells are introduced or transplanted into the subject.
In some embodiments, the ETT polypeptide or the nucleotide sequence encoding the ETT polypeptide is transiently present in the cell or population of cells for about 6 hours to about 7 days, about 6 hours to about 5 days, about 6 hours to about 4 days, about 6 hours to about 3 days, about 6 hours to about 48 hours, about 6 hours to about 36 hours, about 6 hours to about 24 hours, or about 6 hours to about 12 hours.
In some embodiments, the ETT polypeptide or the nucleotide sequence encoding the ETT polypeptide is transiently expressed in the cell or population of cells for about 6 hours to about 7 days, about 6 hours to about 5 days, about 6 hours to about 4 days, about 6 hours to about 3 days, about 6 hours to about 48 hours, about 6 hours to about 36 hours, about 6 hours to about 24 hours, or about 6 hours to about 12 hours.
Selection of Cells
The method according to the present invention comprises selecting the genome edited cells which transiently express or transiently upregulate a nucleotide sequence encoding a selector.
A number of techniques for selecting a cell or a population of cells expressing a selector are known in the art. These include magnetic bead-based separation technologies (e.g. closed-circuit magnetic bead-based separation), flow cytometry, fluorescence-activated cell sorting (FACS), affinity tag purification (e.g. using affinity columns or beads, such biotin columns to separate avidin-labelled agents) and microscopy-based techniques.
It may also be possible to perform the selection using a combination of different techniques, such as a magnetic bead-based separation step followed by sorting of the resulting population of cells for one or more additional (positive or negative) markers by flow cytometry.
Clinical grade separation may be performed, for example, using the CliniMACS® system (Miltenyi) or CliniMACS® Prodigy system (Miltenyi). These are two examples of a closed-circuit magnetic bead-based separation technology.
In the present invention, cells or populations of cells which do not transiently express or transiently upregulate a nucleotide sequence encoding a selector will not be selected.
The technique employed for selecting genome edited cells is preferably one which is amenable to automation and/or high throughput screening.
In some embodiments, the genome edited cells are selected by flow cytometry (such as Fluorescence-activated cell sorting) or magnetic bead separation.
In some embodiments, the genome edited cells are selected by magnetic bead-based separation technologies.
In some embodiments, the genome edited cells are selected by closed-circuit magnetic bead-based separation.
Table B details examples of antibodies suitable for use in selecting for genome edited cells by, for instance, flow cytometry.
Cell Types
In some embodiments, the cell is a mammalian cell. Preferably the cell is a human cell.
In some embodiments, the population of cells are mammalian cells. Preferably the population of cells are human cells.
In some embodiments, the cell is a genome edited cell.
In some embodiments, the population of cells are the starting population of cells. The starting population of cells undergo genome editing according to the method of the present invention. In other embodiments, the population of cells are a population of genome edited cells.
In some embodiments, the cell or population of cells is a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), a myeloid/monocyte-committed progenitor cell, a macrophage or monocyte, a T or B cell lymphocyte, an embryonic stem cell (ESC), induced pluripotent stem cell (iPSC), an epidermal stem cell, a limbal stem cell culture, a mesenchymal stromal cell (MSC), a neural stem cell (NSC), or a mesoangioblast.
In some embodiments, the population of cells are hematopoietic stem cells (HSCs), hematopoietic progenitor cells (HPCs), myeloid/monocyte-committed progenitor cells, macrophages or monocytes, T or B cell lymphocytes, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), epidermal stem cells, limbal stem cell culture, mesenchymal stromal cells (MSCs), neural stem cells (NSCs), mesoangioblasts or a mixture thereof.
A stem cell is able to differentiate into many cell types. A cell that is able to differentiate into all cell types is known as totipotent. In mammals, only the zygote and early embryonic cells are totipotent. Stem cells are found in most, if not all, multicellular organisms. They are characterised by the ability to renew themselves through mitotic cell division and differentiate into a diverse range of specialised cell types. The two broad types of mammalian stem cells are embryonic stem cells that are isolated from the inner cell mass of blastocysts, and adult stem cells that are found in adult tissues. In a developing embryo, stem cells can differentiate into all of the specialised embryonic tissues. In adult organisms, stem cells and progenitor cells act as a repair system for the body, replenishing specialised cells, but also maintaining the normal turnover of regenerative organs, such as blood, skin or intestinal tissues.
Haematopoietic stem cells (HSCs) are multipotent stem cells that may be found, for example, in peripheral blood, bone marrow and umbilical cord blood. HSCs are capable of self-renewal and differentiation into any blood cell lineage. They are capable of recolonising the entire immune system, and the erythroid and myeloid lineages in all the haematopoietic tissues (such as bone marrow, spleen and thymus). They provide for life-long production of all lineages of haematopoietic cells.
Haematopoietic progenitor cells have the capacity to differentiate into a specific type of cell. In contrast to stem cells however, they are already far more specific: they are pushed to differentiate into their “target” cell. A difference between stem cells and progenitor cells is that stem cells can replicate indefinitely, whereas progenitor cells can only divide a limited number of times. Haematopoietic progenitor cells can be rigorously distinguished from HSCs only by functional in vivo assay (i.e. transplantation and demonstration of whether they can give rise to all blood lineages over prolonged time periods).
Haematopoietic Stem and Progenitor Cell (HSPC) Sources
A population of haematopoietic stem and/or progenitor cells may be obtained from a tissue sample.
For example, a population of haematopoietic stem and/or progenitor cells may be obtained from peripheral blood (e.g. adult and foetal peripheral blood), umbilical cord blood, bone marrow, liver or spleen. Preferably, these cells are obtained from peripheral blood or bone marrow. They may be obtained after mobilisation of the cells in vivo by means of growth factor treatment.
Mobilisation may be carried out using, for example, G-CSF, plerixaphor or combinations thereof. Other agents, such as NSAIDs and dipeptidyl peptidase inhibitors, may also be useful as mobilising agents.
With the availability of the stem cell growth factors GM-CSF and G-CSF, most haematopoietic stem cell transplantation procedures are now performed using stem cells collected from the peripheral blood, rather than from the bone marrow. Collecting peripheral blood stem cells provides a bigger graft, does not require that the donor be subjected to general anaesthesia to collect the graft, results in a shorter time to engraftment and may provide for a lower long-term relapse rate.
Bone marrow may be collected by standard aspiration methods (either steady-state or after mobilisation), or by using next-generation harvesting tools (e.g. Marrow Miner).
In addition, haematopoietic stem and progenitor cells may also be derived from induced pluripotent stem cells.
HSC Characteristics
HSCs are typically of low forward scatter and side scatter profile by flow cytometric procedures. Some are metabolically quiescent, as demonstrated by Rhodamine labelling which allows determination of mitochondrial activity. HSCs may comprise certain cell surface markers such as CD34, CD45, CD133, CD90, CD201 and CD49f. They may also be defined as cells lacking the expression of the CD38 and CD45RA cell surface markers. However, expression of some of these markers is dependent upon the developmental stage and tissue-specific context of the HSC. Some HSCs called “side population cells” exclude the Hoechst 33342 dye as detected by flow cytometry. Thus, HSCs have descriptive characteristics that allow for their identification and isolation.
Negative Markers
CD38 is the most established and useful single negative marker for human HSCs.
Human HSCs may also be negative for lineage markers such as CD2, CD3, CD14, CD16, CD19, CD20, CD24, CD36, CD56, CD66b, CD271 and CD45RA. However, these markers may need to be used in combination for HSC enrichment.
By “negative marker” it is to be understood that human HSCs lack the expression of these markers.
Positive Markers
CD34 and CD133 are the most useful positive markers for HSCs.
Some HSCs are also positive for lineage markers such as CD90, CD49f and CD93. However, these markers may need to be used in combination for HSC enrichment.
By “positive marker” it is to be understood that human HSCs express these markers.
In some embodiments, the haematopoietic stem and progenitor cells are CD34+CD38− cells.
Differentiated Cells
A differentiated cell is a cell which has become more specialised in comparison to a stem cell or progenitor cell. Differentiation occurs during the development of a multicellular organism as the organism changes from a single zygote to a complex system of tissues and cell types. Differentiation is also a common process in adults: adult stem cells divide and create fully-differentiated daughter cells during tissue repair and normal cell turnover. Differentiation dramatically changes a cell's size, shape, membrane potential, metabolic activity and responsiveness to signals. These changes are largely due to highly-controlled modifications in gene expression. In other words, a differentiated cell is a cell which has specific structures and performs certain functions due to a developmental process which involves the activation and deactivation of specific genes. Here, a differentiated cell includes differentiated cells of the haematopoietic lineage such as monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes/platelets, dendritic cells, T cells, B-cells and NK-cells. For example, differentiated cells of the haematopoietic lineage can be distinguished from stem cells and progenitor cells by detection of cell surface molecules which are not expressed or are expressed to a lesser degree on undifferentiated cells. Examples of suitable human lineage markers include CD33, CD13, CD14, CD15 (myeloid), CD19, CD20, CD22, CD79a (B), CD36, CD71, CD235a (erythroid), CD2, CD3, CD4, CD8 (T) and CD56 (NK).
The cell or population of cells for use herein may be cultured in any medium suitable for maintaining and/or growing the cells.
Provasi et al (Nat Med 2012 18(5) 807-815; PMID: 22466705) disclose media which are suitable for maintaining and/or growing T cells.
In some embodiments, the cell or population of cells is a K562 cell.
In other embodiments, the cell or population of cells is a CD34+ cell.
Introduction of Components in Cells
The method according to the present invention comprises introducing into a cell or a population of cells at least one first component, at least one second component and at least one third component. The first component, the second component and the third component are discrete and distinct components. Accordingly, at least 3 components are introduced into a cell or a population of cells by the method according to the present invention. In some embodiments, the components used in the method of the present invention are not limited to these three components; additional components might be used in the method depending on, for instance, the specific gene or genes to be targeted.
As used herein, the term “introducing” refers to methods for inserting the components (e.g. foreign DNA or RNA or polypeptide) into a cell. As used herein the term “introducing” includes both transduction and transfection methods. Transfection is the process of introducing the components (e.g. nucleic acids) into a cell by non-viral methods. Transduction is the process of introducing foreign DNA or RNA into a cell via a viral vector.
In some embodiments, the first component and/or second component and/or third component and/or additional component is introduced to the cell by electroporation. In some embodiments, the first component and/or second component and/or third component and/or additional component are introduced to the cell by chemical-based transfection (such as calcium phosphate, cationic polymers (PEI) and liposomes). In some embodiments, the first component and/or second component and/or third component and/or additional component is introduced to the cell by transduction. Suitably, the first component and/or second component and/or third component and/or additional component may be introduced by transduction of a viral vector.
The components used in the method of the present invention may be introduced to the cell or population of cells at the same time or in any order.
In some embodiments, the first component and the second component are introduced into the cell or the population of cells at the same time.
In some embodiments, the first component and the third component are introduced into the cell or the population of cells at the same time.
In some embodiments the second component is introduced into the cell or the population of cells about 1 day to about 14 days after the first component is introduced into the cell or the population of cells. Preferably the second component is introduced into the cell or the population of cells about 2 days to about 4 days after the first component is introduced into the cell or the population of cells.
First Component
The term “first component” as used herein refers to a donor reporter cassette comprising the nucleotide sequence encoding the selector and a nucleotide sequence of interest (NOI).
Donor Reporter Cassette
The term “donor reporter cassette” may be used interchangeably with the terms “donor vector”, “donor DNA vector”, “donor plasmid” and “donor cassette”.
In some embodiments, the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus. This donor reporter cassette is suitable for use in the SMArT method. This donor reporter cassette is suitable for inserting a NOI into a target locus and/or correcting or disrupting a NOI at a target locus.
In other embodiments, the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus. This donor reporter cassette is suitable for use in the SMArT method. This donor reporter cassette is suitable for inserting a NOI into a target locus and/or correcting or disrupting a NOI at a target locus.
In other embodiments, the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates an endogenous promoter in the target locus. This donor reporter cassette is suitable for use in the SMArTER method. This donor reporter cassette is suitable for inserting a NOI into a target locus and/or correcting or disrupting a NOI at a target locus.
Expression of a selector may be increased by use of a binding site for a translational activator and/or an enhancer.
In some embodiments, the donor reporter cassette further comprises at least one binding site for a translational activator such as a modular RNA activator containing the aptamer for eukaryotic initiation factor 4G (eIF4G). The at least one binding site for the translational activator may be inserted downstream and close to the transcriptional start site in order to boost mRNA translation.
In some embodiments, the donor reporter cassette further comprises an enhancer (such as EF1alpha promoter). The enhancer may be inserted close to the promoter.
In some embodiments, the translational activator and/or an enhancer may be inducible in the presence of a modulator. In other embodiments, the translational activator and/or an enhancer may be inducible in the absence of a modulator.
In some embodiments, the donor reporter cassette further comprises a regulatory element.
In some embodiments, the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component binds to the regulatory element and activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus and when a modulator is present in the cell or population of cells. This donor reporter cassette is suitable for use in the SMArT-D method. This donor reporter cassette is suitable for inserting a NOI into a target locus and/or correcting or disrupting a NOI at a target locus.
In other embodiments, the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component binds to the regulatory element and activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus and when a modulator is not present in the cell or population of cells. This donor reporter cassette is suitable for use in the SMArT-D method. This donor reporter cassette is suitable for inserting a NOI into a target locus and/or correcting or disrupting a NOI at a target locus.
In some embodiments, the donor reporter cassette further comprises a splicing acceptor site (SA).
In some embodiments, the 2A self-cleaving peptide (2A) has the sequence shown as SEQ ID NO: 55 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 55.
In some embodiments, the donor reporter cassette further comprises at least one insulator element.
The term “insulator element” as used herein refers to a nucleotide sequence which is capable of limiting the activity of an enhancer on a promoter.
The insulator element may be, for example, derived or derivable from CCCTC-binding factor (CTCF)-dependent or independent binding sites.
In some embodiments the donor reporter cassette comprises an SV40polyA sequence which has the sequence shown as SEQ ID NO: 51 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 51.
In some embodiments, the donor reporter cassette is a plasmid.
In some embodiments, a vector comprises the donor reporter cassette.
In some embodiments, the vector is a plasmid. In other embodiments, the vector is a viral vector.
In some embodiments, the vector is an expression vector.
Homology Arms (HA)
The donor cassette comprises homology arms (HAs). Typically, the donor cassette comprises a left homology arm (left HA) and a right homology arm (right HA).
Each homology arm (HA) comprises a nucleotide sequence which is homologous to at least part of the target locus. Typically, the left homology arm has homology with a sequence at the 5′ end of the target locus and the right homology arm has homology with a sequence at the 3′ end of the target locus.
Homology-directed repair (HDR) is a process where a DNA double-strand break (DSB) (such as in a target locus) is repaired by homologous recombination using a DNA template. Homology driven repair (HDR) can be influenced by the length of the homology arms.
In some embodiments, the left homology arm is about 500 to about 1000 nucleotides in length.
In some embodiments, the left homology arm has the sequence shown as SEQ ID NO: 50 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 50.
In other embodiments, the left homology arm is between about 50 to about 500 nucleotides in length.
In other embodiments, the left homology arm is between about 50 to about 600 nucleotides in length.
In some embodiments the left homology arm is between about 80 to about 200 nucleotides in length. Preferably the left homology arm is between about 130 to about 170 nucleotides in length. Preferably the left homology arm is between about 140 to about 160 nucleotides in length. More preferably the left homology arm is about 150 nucleotides in length.
In some embodiments, the left HA has the sequence shown as SEQ ID NO: 52 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 52.
In some embodiments the left homology arm is between about 200 to about 350 nucleotides in length. Preferably the left homology arm is between about 250 to about 330 nucleotides in length. Preferably the left homology arm is between about 280 to about 310 nucleotides in length. More preferably the left homology arm is about 290 nucleotides in length.
In some embodiments, the left HA has the sequence shown as SEQ ID NO: 53 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 53.
In some embodiments, the left HA has the sequence shown as SEQ ID NO: 61 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 61.
In some embodiments, the left HA has the sequence shown as SEQ ID NO: 63 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 63.
In some embodiments, the right homology arm is about 500 to about 1000 nucleotides in length.
In other embodiments the right homology arm is between about 200 to about 300 nucleotides in length. Preferably the right homology arm is between about 250 to about 290 nucleotides in length. Preferably the right homology arm is between about 260 to about 280 nucleotides in length. More preferably the left homology arm is about 270 nucleotides in length.
In some embodiments, the right HA has the sequence shown as SEQ ID NO: 56 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 56.
In some embodiments, the right HA has the sequence shown as SEQ ID NO: 62 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 62.
In some embodiments, the right HA has the sequence shown as SEQ ID NO: 64 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 64.
Typically, inserts between the left homology arm and the right homology arm can be about 1000 to about 2000 nucleotides in length.
Target Locus
The term “target locus” as used herein may be used interchangeably with the term “target gene”. The target locus is a desired site in a genome for insertion (or integration), correction, mutation or deletion.
The target locus can be any locus in the genome of a cell.
In some embodiments, the target locus is a safe harbour. The term “safe harbour” as used herein refers to a location in the genome in which the integration of a nucleotide sequence does not disrupt any regulatory or coding sequence nor perturb the nearest regulatory elements or the transcriptional profiling of neighbouring genes. The term “safe harbour” may be used interchangeably with the terms “neutral area”, “neutral region” and “neutral gene”.
In some embodiments, the target locus is adeno-associated virus integration site 1 (AAVS1) or a common integration site (CIS) of lentiviral vectors.
In other embodiments, the target locus is IL2RG, gp91phox, HBB, RAG1, CD40LG, TRAC, TRBC, STAT or PRF1.
In other embodiments, the target locus is a gene encoding for a protein expressed in the skin such as collagen, keratin, laminin, desmocolin, desmoplachine, desmoglein, placoglobin, placophylline, integrin or other proteins that are involved in desmosomes and hemidesmosomes.
In some embodiments, the target locus is adeno-associated virus integration site 1 (AAVS1).
In other embodiments, the target locus is IL2RG.
In other embodiments, the target locus is CD40LG.
In some embodiments, the genome of the cell comprises at least one ETT binding site operably linked to the target locus.
In some embodiments, an endogenous promoter is operably linked to the at least one ETT binding site. In some embodiments, the ETT binding site is located downstream of the endogenous promoter. In other embodiments, the ETT binding site is located upstream of the endogenous promoter. Without wishing to be bound by theory, the ETT binding site acts as an enhancer.
In some embodiments, the ETT binding site comprises a nucleotide sequence having the sequence shown as any one of SEQ ID NOs 32 to 40 or a sequence having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto. Preferably the ETT binding site comprises a nucleotide sequence having the sequence shown as SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 38. More preferably the ETT binding site comprises a nucleotide sequence shown as SEQ ID NO: 34 or SEQ ID NO: 38.
In some embodiments, the ETT binding site comprises a nucleotide sequence encoding at least one tetO sequence.
In some embodiments, the ETT binding site comprises a nucleotide sequence having the sequence shown SEQ ID NO: 65 or a sequence having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
Selector
The terms “nucleotide sequence encoding the selector”, “reporter”, “reporter gene”, “marker” and “selector” may be used interchangeably. As used herein the term “nucleotide sequence encoding the selector” refers to any nucleotide sequence which can be used to select cells in which the nucleotide sequence has been inserted into the target locus (desired integration site) in the genome from cells in which the nucleotide sequence has not been inserted or in which the sequence is inserted into the wrong site.
In some embodiments, cells in which a selector has been inserted into the wrong site will not express the selector. In other embodiments, (such as SMArT-D) cells in which the selector is inserted into a non-target site will express the selector.
In some embodiments, the nucleotide sequence encoding the selector encodes a selector selected from the group consisting of: mutated low-affinity nerve growth factor receptor (ΔLNGFR); truncated NGFR; a drug-resistance protein (such as proteins having neomycin or puromycin resistance, or mutated methylguanine DNA methyltransferase (MGMT)); truncated cell surface proteins (such as CD19 and EGFR-PMID: 21653320, Wang et al Blood 118(5):1255-63); proteins that confer selective growth and/or engraftment advantage after in vivo transplantation of the genome edited cell (such as receptor tyrosine kinase (c-Kit), C-X-C chemokine receptor type 4 (CXCR4, or CXCR4 WHIM) and CD47) and reporter proteins (for example, fluorescent proteins such as eGFP).
In some embodiments, the nucleotide sequence encoding the selector encodes a nerve growth factor receptor such as a low-affinity nerve growth factor receptor or a mutated low-affinity nerve growth factor receptor (ΔLNGFR). Examples of nucleotide sequences encoding nerve growth factor receptor are SEQ ID NO: 44 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto. Other Examples of nucleotide sequences encoding nerve growth factor receptor (NGFR) are SEQ ID NO: 67 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In other embodiments, the nucleotide sequence encoding the selector encodes a reporter protein such as eGFP. The term “eGFP” may be used herein interchangeably with the term “GFP”. Examples of nucleotide sequences encoding GFP are SEQ ID NO: 43 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the nucleotide sequence encoding the selector is selected from the group consisting of SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 67 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the nucleotide sequence encoding the selector is fused to at least one nucleotide sequence encoding a destabilizer domain.
The term “destabilizer domain” as used herein refers to polypeptides capable of conferring instability to a polypeptide. For example, the destabilizer domains are able to introduce proteasomal degradation of the selector in the absence of specific stabilizer ligands.
In some embodiments, the destabilizer domain is a ligand-regulatable destabilizing domain. Examples of ligand-regulatable destabilizing domains include FKBP domains, bacterial DHFR and estrogen receptors (such as human estrogen receptors).
In some embodiments, the nucleotide sequence encoding the selector is operably linked to a promoter.
In some embodiments, the nucleotide sequence encoding the selector is operably linked to a minimal promoter.
The term “minimal promoter” as used herein refers to the minimal elements of a promoter, such the TATA box and transcription initiation site, which are inactive unless regulatory elements that enhance promoter activity are placed upstream.
In some embodiments, the minimal promoter is selected from the group consisting of synthetic promoter T6-SK and cytomegalovirus (CMV).
In some embodiments, the T6-SK promoter has the sequence shown as SEQ ID NO: 41 or a has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the sequence shown as SEQ ID NO: 41.
In some embodiments, the CMV promoter has the sequence shown as SEQ ID NO: 42 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to SEQ ID NO: 42.
In some embodiments, the minimal promoter is operably linked to a regulatory element.
In some embodiments, the minimal promoter SK is operably linked to a regulatory element.
In some embodiments, the minimal promoter SK is operably linked to a regulatory element which has the sequence shown as SEQ ID NO: 41 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the sequence shown as SEQ ID NO: 65.
In some embodiments, the minimal promoter SK is operably linked to a regulatory element which has the sequence shown as SEQ ID NO: 65.
The terms “T6-SK” and “S K” may be used interchangeably herein.
Regulatory Element
The term “regulatory element” as used herein refers to a nucleotide sequence which is capable of activating or enhancing the activity of a promoter.
Typically, at least one regulatory element is placed upstream of the promoter.
In other embodiments, the at least one regulatory element is placed elsewhere such as downstream of the promoter.
Examples of regulatory elements include translational activators and enhancers.
In some embodiments, the regulatory element activates or enhances the activity of a promoter.
In some embodiments, the regulatory element is inducible.
Among the inducible systems, the most extensively studied and tested is the TetO system, which allows to induce transient transactivation of the downstream gene (Gossen & Bujard, 1992). Tet-OFF systems consists of: i) Tet operon (TetO) derived from Escherichia coli, placed upstream of a minimal promoter, which can also be present in multiple copies; ii) the tetracycline transactivator (tTA) protein composed by the fusion of Tet repressor (TetR), derived from Escherichia coli, and multiple repeats of the activator domain VP16 from Herpes Simplex Virus. In the absence of tetracycline (or its derivatives as doxycycline), tTA binds TetO sequence(s) and induces transactivation of the gene under the control of the minimal promoter. The system can be turned off when tetracycline or its derivatives bind tTA, thus preventing tTA tethering on TetO. In Tet-ON systems the rtTA is able to bind TetO sequence(s) only in presence of tetracycline or derivatives.
Without wishing to be bound by theory, the ETT polypeptide binds to the regulatory element and this binding activates or enhances the activity of the promoter.
In some embodiments, the regulatory element comprises at least one tetracyclin operator (TetO) sequence.
In some embodiments, the regulatory element comprises at least 2, 3, 4, 5, 6, 7 or 8 TetO sequences. In some embodiments, the regulatory element comprises at least 2 TetO sequences. In other embodiments, the regulatory element comprises at least 7 TetO sequences.
In one embodiment, the regulatory element comprises 2 TetO sequences. This may be referred to as TetO2.
In another embodiment, the regulatory element comprises 7 TetO sequences. This may be referred to as TetO7.
Without wishing to be bound by theory, the binding of several tTA or rtTAs to the TetO sequences repeats enhances transactivation of the selector which, in turn, enhances the selection of the genome edited cells.
Typically the TetO sequence (TCCCTATCAGTGATAGAGA) (SEQ ID NO: 59) separated by spacer sequences (for example: ACGATGTCGAGTTTAC) (SEQ ID NO: 60).
In some embodiments, the TetO sequence has the sequence TCCCTATCAGTGATAGAGA.
In some embodiments, the TetO sequence has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the sequence TCCCTATCAGTGATAGAGA (SEQ ID NO: 59).
In some embodiments, the TetO sequence has the sequence shown as SEQ ID NO: 65 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 65.
In some embodiments, the TetO7 sequence has the sequence shown as SEQ ID NO: 65 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 65.
In some embodiments, the TetO sequence has the sequence CCCTATCAGMATAGAGA (SEQ ID NO: 66).
In some embodiments, the TetO sequence has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the sequence CCCTATCAGTGATAGAGA (SEQ ID NO: 66).
In some embodiments, the TetO sequence has the sequence shown as SEQ ID NO: 76 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 76.
In some embodiments, the TetO7 sequence has the sequence shown as SEQ ID NO: 76 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 76.
In some embodiments, the ETT polypeptide expressed by the second component or the ETT polypeptide of the second component which binds to the regulator element is tetracyclin transactivator (tTA).
The tetracyclin transactivator (tTA) is capable of binding to the TetO sequence.
The tetracyclin transactivator (tTA) as used herein comprises the DNA binding domain (DBD) TetR and the transcriptional activator (TA) domain VP16.
An example of tetracyclin transactivator (tTA) is shown in SEQ ID NO: 58.
In some embodiments, the nucleotide sequence encoding tetracyclin transactivator (tTA) has the sequence shown as SEQ ID NO: 58 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 58.
In some embodiments, the nucleotide sequence encoding tetR has the sequence shown as SEQ ID NO: 74 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 74.
In some embodiments, the nucleotide sequence encoding VP16 has the sequence shown as SEQ ID NO: 75 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 75.
In other embodiments, the ETT polypeptide expressed by the second component or the ETT polypeptide of the second component which binds to the regulator element is reverse-tTA (rtTA).
In some embodiments, reverse-tTA (rtTA) has the sequence:
In some embodiments, reverse-tTA (rtTA) has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 70.
In some embodiments, reverse-tTA (rtTA) has the sequence:
In some embodiments, reverse-tTA (rtTA) has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 70.
The reverse tetracyclin transactivator (rtTA) is capable of binding to the TetO sequence when a modulator (such as a tetracycline (Tc) or a tetracycline derivative (e.g. deoxycycline)) is bound to the rtTA.
In the SMArT-D strategy the transactivator might not activate selector expression exclusively from the integrated donor reporter cassette but also from the unintegrated donor reporter donor, if present. However, tTA activity may be modified (up to complete inhibition) by a modulator (such as tetracycline or doxycycline treatment), which could enable upregulated or exclusive expression of the selector from cells in which the donor reporter cassette is integrated.
Advantageously, the SMArT-D strategy can be used with any target locus of interest without the need to design and screen gene-specific transactivators.
In some embodiments, binding of tTA or rtTA occurs close to the transcriptional start site (TSS). Without wishing to be bound by theory, the binding of tTA or rtTA close to the transcriptional start site (TSS) improves transactivation efficiency.
Modulator
The term “modulator” as used herein refers to any composition capable of binding to the ETT polypeptide, in particular the DNA binding domain (DBD), which modulates the activity, in particular DNA binding activity, of the ETT polypeptide
Examples of modulators of tetracyclin transactivator (tTA) and reverse tetracyclin transactivator (rtTA) are tetracyclines (Tc) and tetracycline derivatives such as deoxycycline (dox).
In one embodiment, the modulator is selected from the group consisting of tetracyclines (Tc), tetracycline derivatives (such as deoxycycline (dox)) and combinations thereof.
In one embodiment, the modulator is a tetracycline derivative.
In one embodiment, the modulator is deoxycycline.
Without wishing to be bound by theory, the binding of a modulator (such as tetracycline (Tc) or a tetracycline derivatives (such as dox) induces conformational changes in the DBD (such as the TetR domain) that prevents binding to the regulatory element (such as binding to the tetO sequence) if the donor reporter cassette has not been inserted into the genome; consequently the selector is not expressed. Conversely, cells in which the donor cassette has been inserted are still able to express the selector. Thus cells can be selected in which the donor cassette has been inserted.
Without wishing to be bound by theory, the binding of a modulator (such as tetracycline (Tc) or a tetracycline derivatives (such as dox) induces conformational changes in the DBD (such as reverse-TetR domain) that enables the DBD to bind to the regulatory element (such as the tetO sequence) when the donor reporter cassette has been inserted into the genome; consequently the selector is expressed. Conversely, cells in which the donor cassette has been inserted do express the selector. Thus cells can be selected in which the donor cassette has been inserted.
The modulator may be added to the cell or population of cells before, or after, or at the same time as the first component and/or second component and/or third component are introduced into the cell or population of cells.
In some embodiments, the modulator is added to the cell or population of cells about 6 hours to about 36 hours, about 6 hours to about 24 hours, or about 6 hours to about 12 hours after, the first component and/or second component and/or third component are introduced into the cell or population of cells.
The optimal dosage of a modulator may depend on multiple factors such as the donor reporter cassette, the target locus, and the nature of the cell or population of cells. The skilled person can readily determine an appropriate dose of the modulator (e.g. dox) to administer to the cell or population of cells.
In some aspect, the modulator (e.g. dox) is administered to the cell or population of cells so that about 10 nM to about 2 mM, or about 50 nM to about 1 mM, or about 80 nM to about 800 μM, or about 100 nM to 500 μM of the modulator is present in the media.
For example, the modulator (e.g. dox) is administered to the cell or population of cells so that at least 10 nM, at least 25 nM, at least 50 nM, at least 80 nM, at least 100 nM, at least 200 nM, at least 300 nM, at least 400 nM, at least 500 nM, at least 100 mM, or at least 200 mM of the modulator is present in the media.
The skilled person can readily determine when to wash the cell or population of cells treated with the modulator. This washing may be referred to as modulator (e.g. dox) withdrawal or washout.
The cell or population of cells treated with a modulator may be washed at least once, at least twice, at least thrice with a buffer solution (e.g. PBS) or a media which is suitable for maintaining and/or growing the cell or population of cells.
The cell or population of cells may be washed at least 6 hours, at least 12 hours, at least 18 hours, at least 21 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours after treatment with a modulator and/or introduction of the first component and/or second component and/or third component into the cell or population of cells.
The edited cell or population of edited cells may be exposed to the modulator for at least 6 hours, at least 12 hours, at least 18 hours, at least 21 hours, at least 24 hours, at least 30 hours, at least 36 hours, at least 48 hours, at least 60 hours, or at least 72 hours after treatment the introduction of the first component and/or second component and/or third component into the cell or population of cells.
NOI
The term “NOI” may be used interchangeably with the term “GOI”, “gene of interest” or “corrective cDNA”.
In some embodiments, the NOI is IL2RG, gp91phox, HBB, RAG1, CD40LG, TRAC, TRBC, STAT or PRF1.
In other embodiments, the NOI is a gene encoding for a protein expressed in the skin such as collagen, keratin, laminin, desmocolin, desmoplachine, desmoglein, placoglobin, placophylline, integrin or other proteins that are involved in desmosomes and hemidesmosomes.
In some embodiments, the NOI is IR2RG. Examples of NOI encoding IR2LG are SEQ ID NO: 54 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the NOI is selected from the group consisting of SEQ ID NO: 54 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the NOI is operably linked to a promoter.
In some embodiments, the nucleotide sequence encoding the selector and the NOI may be the same.
The term “transcription starting site (TSS)” as used herein refers to the first nucleotide where RNA polymerase begins to synthesize the RNA transcript.
In some embodiments, the NOI is about 50 to about 400 nucleotides downstream of a transcription starting site (TSS). Preferably the NOI about 100 to about 250 nucleotides downstream of the TSS.
Second Component
The term “second component” as used herein refers to an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide.
The term “ETT polypeptide” as used herein refers to a polypeptide comprising a DNA binding domain (DBD) and at least one transcription activator (TA) domain.
The ETT polypeptide of the second component or the ETT polypeptide expressed by the second component binds to an ETT binding site in the genome of the cell.
In one embodiment, the ETT binding site is a regulatory element.
In one embodiment, the ETT binding site is one or more tetO sequences.
In some embodiments, the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus. Typically this results in expression of the selector.
In other embodiments, the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates an endogenous promoter in the target locus. Typically, when a nucleotide sequence encoding the selector is inserted into the target locus the selector is expressed.
In some embodiments, the nucleotide sequence encoding an ETT polypeptide is a plasmid.
In some embodiments, a vector comprises the nucleotide sequence encoding an ETT polypeptide.
In some embodiments, the vector is a plasmid. In other embodiments, the vector is a viral vector.
In some embodiments, the vector is an expression vector.
DNA Binding Domain (DBD)
DNA binding domains (DBDs) contain at least one structural motif that recognizes double- or single-stranded DNA.
Examples of DBD for use in the present invention include, but are not limited to, transcriptional activator-Like effector (TALE) DBDs (such as TALE7 DBD and TALE3 DBD), zinc fingers (ZNF), catalytically inactive Cpf1 and catalytically inactive Cas (dCas) (such as dCas9).
Additional examples of DBD for use in the present invention include TetR and reverseTetR.
Catalytically inactive Cas variants (such as dCas9) have been isolated from various bacteria (such as S. aureus, S. thermophilus, and N. meningitidis)—see Ran et al., Nature 2015 (PMID: 25830891), Lee et al., Mol Ther 2016 (PMID: 26782639)). Zetsche et al., (Cell 2015 pii: S0092-8674(15)01200-3 (PMID: 26422227)) discloses other Cas protein (such as Cpf1).
In some embodiments, the DBD is a TALE.
In some embodiments, the DBD is a catalytically inactive Cas (dCas). Preferably, the dCas is dCas9.
In some embodiments the DBD is tTA.
In other embodiments, the DBD is rtTA.
In some embodiments, the DBD is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 48, SEQ ID NO: 49 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the DBD is capable of binding to one or more of the nucleotide sequences selected from the group consisting of SEQ ID NOs 32 to 40 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto. In some embodiments, the DBD is capable of binding to one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34 and SEQ ID NO: 38. Preferably, the DBD is capable of binding to SEQ ID NO: 34 or SEQ ID NO: 38.
Transcription Activator (TA) Domain
Transcription activator (TA) domains contain binding sites for polypeptides which activate transcription.
Examples of TA domains for use in the present invention include, but are not limited to, VP16, VP64, VP128, VP160, VPR, p65, Rta, HSF1, synergistic activation mediator (SAM), and SunTag.
In some embodiments, the TA is VPR. In other embodiments, the TA is VP160. In other embodiments, the TA is VP16.
In some embodiments, the TA domain is encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO: 46, SEQ ID NO: 47, and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the second component is an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide; wherein the ETT polypeptide comprises a DNA binding domain (DBD) and at least one transcription activator (TA) domain;
In other embodiments, the second component is an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide; wherein the ETT polypeptide comprises a DNA binding domain (DBD) and at least one transcription activator (TA) domain;
In some embodiments, the second component is an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide; wherein the ETT polypeptide comprises TetR and at least one VP16.
In some embodiments, the second component is a nucleotide sequence encoding an ETT polypeptide wherein the nucleotide sequence has the sequence shown as SEQ ID NO: 58 or has at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity to the nucleotide sequence shown as SEQ ID NO: 58.
In some embodiments, the second component is an engineered transcriptional transactivator (ETT) polypeptide or a nucleotide sequence encoding an ETT polypeptide; wherein the ETT polypeptide comprises reverse-TetR and at least one VP16.
Third Component
The term “third component” as used herein refers to a nuclease system comprising a genome targeted nuclease. The nuclease system cuts and/or repairs genomic DNA. The presence of the nuclease system in a cell or a population of cells enables the insertion of the nucleotide sequence encoding the selector (and, optionally, a minimal promoter) and the correction or insertion or deletion or mutation of a NOI in the target locus.
The genome targeted nuclease is provided as a protein, RNA, DNA, or an expression vector comprising a nucleic acid sequence that encodes the genome targeted nuclease.
In some embodiments, the expression vector is a plasmid. In other embodiments, the expression vector is a viral vector.
In some embodiments, the genome targeted nuclease is a transcriptional activator-like effector nuclease (TALEN), a zinc finger nuclease (ZNF), a CRISPR-Cas (such as CRISPR-Cas9, or SpCas9, or CRISPR-Cpf (such as CRISPR-Cpf1)) or a meganuclease.
In some embodiments, the third component additionally comprises a guide RNA comprising at least one targeted genomic sequence. Guide RNA comprising at least one targeted genomic sequence is capable of binding to at least one sequence in the genome of a cell.
Typically, the third component additionally comprises a guide RNA when the genome targeted nuclease is a CRISPR-Cas (such as CRISPR-Cas9 or CRISPR-Cpf (such as CRISPR-Cpf1)). Typically the guide RNA is delivered simultaneously with the genome targeted nuclease. In some embodiments, the guide RNA is delivered before or after the genome targeted nuclease.
The guide RNA (gRNA) is provided as an RNA molecule, DNA molecule, or an expression vector comprising a nucleic acid sequence that encodes the gRNA.
In some embodiments, the expression vector is a plasmid. In other embodiments, the expression vector is a viral vector.
In some embodiments, the gRNA is capable of binding to the target locus AAVS1.
In some embodiments, the gRNA is capable of binding to the target locus IL2RG.
In some embodiments, the gRNA is capable of binding to the target locus CD40LG.
Typically, the gRNA binds upstream of the promoter.
In some embodiments, the gRNA is capable of binding to the nucleotide sequence
In other embodiments, the gRNA is capable of binding to the nucleotide sequence
In other embodiments, the gRNA is capable of binding to the nucleotide sequence
In some embodiments the gRNA is capable of binding to one or more of the nucleotide sequences selected from the group consisting of SEQ ID NOs 1 to 31 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto. Suitably the gRNA is capable of binding to one or more of the nucleotide sequences selected from the group consisting of SEQ ID NOs 1 to 18 and 21 to 31 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto. Preferably the gRNA is capable of binding to one or more nucleotide sequences selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 12.
In some embodiments the gRNA is capable of binding to one or more of the nucleotide sequences selected from the group consisting of SEQ ID NOs: 70 to 72 and sequences having at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identity thereto.
In some embodiments, the guide RNA (gRNA) is provided as a single guide RNA capable of binding to one nucleotide sequence. In other embodiments, the guide RNA is provided as a combination of two types of guide RNA each capable of binding to a different nucleotide sequence. For example, the guide RNA is provided as a combination of two types of guide RNA of which one is capable of binding to SEQ ID NO: 4 and the other is capable of binding to SEQ ID NO: 12. In other embodiments, the guide RNA is provided as a combination of three types of guide RNA each capable of binding to a different nucleotide sequence. In other embodiments, the guide RNA is provided as a combination of four types of guide RNA each capable of binding to a different nucleotide sequence. In other embodiments, the guide RNA is provided as a combination of at least five types of guide RNA each capable of binding to a different nucleotide sequence.
In some embodiments, the nuclease system is in the form of ribonucleoprotein (RNP).
In some embodiments, the nuclease system is an RNP comprising CRISPR-Cas. For example, the nuclease system is an RNP comprising CRISPR-Cas and cr:tracrRNA (Integrated DNA technologies).
Preferably, the third component is a nuclease system comprising CRISPR-Cas and a guide RNA.
Preferably, the third component is a nuclease system comprising CRISPR-Cpf and a guide RNA.
Variants
In addition to the specific polypeptides and polynucleotides mentioned herein, the present invention also encompasses the use of variants.
Variant sequences of SEQ ID NOs recited herein may have at least 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% sequence identity to the reference sequence SEQ ID NOs. Preferably, the variant sequence retains one or more functions of the reference sequence (i.e. is a functional variant).
Variant sequences may comprise substitutions, additions, deletions and/or insertions.
Variant sequences may comprise one or more conservative substitutions. Conservative amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino acids with uncharged polar head groups having similar hydrophilicity values include leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.
Conservative substitutions may be made, for example according to the Table below. Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:
The present invention also encompasses homologous substitution (substitution and replacement are both used herein to mean the interchange of an existing amino acid residue, with an alternative residue) variants i.e. like-for-like substitution such as basic for basic, acidic for acidic, polar for polar etc.
Unless otherwise explicitly stated herein by way of reference to a specific, individual amino acid, amino acids may be substituted using conservative substitutions as recited below.
An aliphatic, non-polar amino acid may be a glycine, alanine, proline, isoleucine, leucine or valine residue.
An aliphatic, polar uncharged amino may be a cysteine, serine, threonine, methionine, asparagine or glutamine residue.
An aliphatic, polar charged amino acid may be an aspartic acid, glutamic acid, lysine or arginine residue.
An aromatic amino acid may be a histidine, phenylalanine, tryptophan or tyrosine residue.
Suitably, a conservative substitution may be made between amino acids in the same line in the Table above.
In some embodiments, the sequence is codon optimized for the subject.
Vectors
In some embodiments, a vector comprises the first component (i.e. the vector comprises the donor cassette).
In some embodiments, a vector comprises a nucleotide sequence encoding an ETT polypeptide.
In some embodiments, a vector comprises a nucleotide sequence encoding a nuclease.
A vector is a tool that allows or facilitates the transfer of an entity from one environment to another.
The vector may be single-stranded or double-stranded.
The vector may be an integrase-deficient vector such as a integrase-deficient lentiviral vector (IDLV).
In some embodiments, the vectors used in the present invention are plasmids. In other embodiments, the vectors used in the present invention are viral vectors.
In some embodiments, the viral vector is in the form of a viral vector particle.
In some embodiments, the components are a mixture of different types of vectors. For example, the first component is in the form of a viral vector, the second component is in the form of a plasmid vector and the third component is in the form of a plasmid vector
The viral vector may be, for example, an adeno-associated viral (AAV), adenoviral, a retroviral or lentiviral vector. Preferably, the viral vector is an AAV vector or a retroviral or lentiviral vector, more preferably an AAV vector.
By “vector derived from” a certain type of virus, it is to be understood that the vector comprises at least one component part derivable from that type of virus.
Adeno-Associated Viral (AAV) Vectors
Adeno-associated virus (AAV) is an attractive vector system for use in the invention as it has a high frequency of integration and it can infect non-dividing cells. This makes it useful for delivery of genes into mammalian cells in tissue culture.
AAV has a broad host range for infectivity. Details concerning the generation and use of AAV vectors are described in U.S. Pat. Nos. 5,139,941 and 4,797,368.
Recombinant AAV vectors have been used successfully for in vitro and in vivo transduction of marker genes and genes involved in human diseases.
Preferred vectors are those which are able to achieve a high transduction efficiency in human primary cells, such as HSPC cells.
In some embodiments, the vector is an AAV6 vector or a vector derived from an AAV6 vector. Preferably the vector is an AAV6 vector.
Adenoviral Vectors
The adenovirus is a double-stranded, linear DNA virus that does not go through an RNA intermediate. There are over 50 different human serotypes of adenovirus divided into 6 subgroups based on the genetic sequence homology. The natural targets of adenovirus are the respiratory and gastrointestinal epithelia, generally giving rise to only mild symptoms. Serotypes 2 and 5 (with 95% sequence homology) are most commonly used in adenoviral vector systems and are normally associated with upper respiratory tract infections in the young.
Adenoviruses have been used as vectors for gene therapy and for expression of heterologous genes. The large (36 kb) genome can accommodate up to 8 kb of foreign insert DNA and is able to replicate efficiently in complementing cell lines to produce very high titres of up to 1012. Adenovirus is thus one of the best systems to study the expression of genes in primary non-replicative cells.
The expression of viral or foreign genes from the adenovirus genome does not require a replicating cell. Adenoviral vectors enter cells by receptor mediated endocytosis. Once inside the cell, adenovirus vectors rarely integrate into the host chromosome. Instead, they function episomally (independently from the host genome) as a linear genome in the host nucleus. Hence the use of recombinant adenovirus alleviates the problems associated with random integration into the host genome.
Retroviral and Lentiviral Vectors
A retroviral vector may be derived from or may be derivable from any suitable retrovirus. A large number of different retroviruses have been identified. Examples include murine leukaemia virus (MLV), human T-cell leukaemia virus (HTLV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukaemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson murine leukaemia virus (A-MLV), avian myelocytomatosis virus-29 (MC29) and avian erythroblastosis virus (AEV). A detailed list of retroviruses may be found in Coffin, J. M. et al. (1997) Retroviruses, Cold Spring Harbour Laboratory Press, 758-63.
Retroviruses may be broadly divided into two categories, “simple” and “complex”. Retroviruses may be even further divided into seven groups. Five of these groups represent retroviruses with oncogenic potential. The remaining two groups are the lentiviruses and the spumaviruses. A review of these retroviruses is presented in Coffin, J. M. et al. (1997) Retroviruses, Cold Spring Harbour Laboratory Press, 758-63.
The basic structure of retrovirus and lentivirus genomes share many common features such as a 5′ LTR and a 3′ LTR. Between or within these are located a packaging signal to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome, and gag, pol and env genes encoding the packaging components—these are polypeptides required for the assembly of viral particles. Lentiviruses have additional features, such as rev and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the integrated provirus from the nucleus to the cytoplasm of an infected target cell.
In the provirus, these genes are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration and transcription. LTRs also serve as enhancer-promoter sequences and can control the expression of the viral genes.
The LTRs themselves are identical sequences that can be divided into three elements: U3, R and U5. U3 is derived from the sequence unique to the 3′ end of the RNA. R is derived from a sequence repeated at both ends of the RNA. U5 is derived from the sequence unique to the 5′ end of the RNA. The sizes of the three elements can vary considerably among different retroviruses.
In a defective retroviral vector genome gag, pol and env may be absent or not functional.
In a typical retroviral vector, at least part of one or more protein coding regions essential for replication may be removed from the virus. This makes the viral vector replication-defective. Portions of the viral genome may also be replaced by a library encoding candidate modulating moieties operably linked to a regulatory control region and a reporter moiety in the vector genome in order to generate a vector comprising candidate modulating moieties which is capable of transducing a target host cell and/or integrating its genome into a host genome.
Lentivirus vectors are part of the larger group of retroviral vectors. A detailed list of lentiviruses may be found in Coffin, J. M. et al. (1997) Retroviruses, Cold Spring Harbour Laboratory Press, 758-63. In brief, lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include but are not limited to human immunodeficiency virus (HIV), the causative agent of human acquired immunodeficiency syndrome (AIDS); and simian immunodeficiency virus (SIV). Examples of non-primate lentiviruses include the prototype “slow virus” visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV), and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).
The lentivirus family differs from retroviruses in that lentiviruses have the capability to infect both dividing and non-dividing cells (Lewis, P et al. (1992) EMBO J. 11: 3053-8; Lewis, P. F. et al. (1994) J. Virol. 68: 510-6). In contrast, other retroviruses, such as MLV, are unable to infect non-dividing or slowly dividing cells such as those that make up, for example, muscle, brain, lung and liver tissue.
A lentiviral vector, as used herein, is a vector which comprises at least one component part derivable from a lentivirus. Preferably, that component part is involved in the biological mechanisms by which the vector infects cells, expresses genes or is replicated.
The lentiviral vector may be a “primate” vector. The lentiviral vector may be a “non-primate” vector (i.e. derived from a virus which does not primarily infect primates, especially humans). Examples of non-primate lentiviruses may be any member of the family of lentiviridae which does not naturally infect a primate.
As examples of lentivirus-based vectors, HIV-1- and HIV-2-based vectors are described below.
The HIV-1 vector contains cis-acting elements that are also found in simple retroviruses. It has been shown that sequences that extend into the gag open reading frame are important for packaging of HIV-1. Therefore, HIV-1 vectors often contain the relevant portion of gag in which the translational initiation codon has been mutated. In addition, most HIV-1 vectors also contain a portion of the env gene that includes the RRE. Rev binds to RRE, which permits the transport of full-length or singly spliced mRNAs from the nucleus to the cytoplasm. In the absence of Rev and/or RRE, full-length HIV-1 RNAs accumulate in the nucleus. Alternatively, a constitutive transport element from certain simple retroviruses such as Mason-Pfizer monkey virus can be used to relieve the requirement for Rev and RRE. Efficient transcription from the HIV-1 LTR promoter requires the viral protein Tat.
Most HIV-2-based vectors are structurally very similar to HIV-1 vectors. Similar to HIV-1-based vectors, HIV-2 vectors also require RRE for efficient transport of the full-length or singly spliced viral RNAs.
In one system, the vector and helper constructs are from two different viruses, and the reduced nucleotide homology may decrease the probability of recombination. In addition to vectors based on the primate lentiviruses, vectors based on FIV have also been developed as an alternative to vectors derived from the pathogenic HIV-1 genome. The structures of these vectors are also similar to the HIV-1 based vectors.
Preferably, the viral vector used in the present invention has a minimal viral genome.
By “minimal viral genome” it is to be understood that the viral vector has been manipulated so as to remove the non-essential elements and to retain the essential elements in order to provide the required functionality to infect, transduce and deliver a nucleotide sequence of interest to a target host cell. Further details of this strategy can be found in WO 1998/017815.
Preferably, the plasmid vector used to produce the viral genome within a host cell/packaging cell will have sufficient lentiviral genetic information to allow packaging of an RNA genome, in the presence of packaging components, into a viral particle which is capable of infecting a target cell, but is incapable of independent replication to produce infectious viral particles within the final target cell. Preferably, the vector lacks a functional gag-pol and/or env gene and/or other genes essential for replication.
However, the plasmid vector used to produce the viral genome within a host cell/packaging cell will also include transcriptional regulatory control sequences operably linked to the lentiviral genome to direct transcription of the genome in a host cell/packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed viral sequence (i.e. the 5′ U3 region), or they may be a heterologous promoter, such as another viral promoter (e.g. the CMV promoter).
The vectors may be self-inactivating (SIN) vectors in which the viral enhancer and promoter sequences have been deleted. SIN vectors can be generated and transduce non-dividing cells in vivo with an efficacy similar to that of wild-type vectors. The transcriptional inactivation of the long terminal repeat (LTR) in the SIN provirus should prevent mobilisation by replication-competent virus. This should also enable the regulated expression of genes from internal promoters by eliminating any cis-acting effects of the LTR.
The vectors may be integration-defective. Integration defective lentiviral vectors (IDLVs) can be produced, for example, either by packaging the vector with catalytically inactive integrase (such as an HIV integrase bearing the D64V mutation in the catalytic site; Naldini, L. et al. (1996) Science 272: 263-7; Naldini, L. et al. (1996) Proc. Natl. Acad. Sci. USA 93: 11382-8; Leavitt, A. D. et al. (1996) J. Virol. 70: 721-8) or by modifying or deleting essential att sequences from the vector LTR (Nightingale, S. J. et al. (2006) Mol. Ther. 13: 1121-32), or by a combination of the above.
Pharmaceutical Composition
In some embodiments, the population of genome edited cells produced or prepared according to a method of the invention may be formulated for administration to subjects with a pharmaceutically acceptable carrier, diluent or excipient. Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline, and potentially contain human serum albumin.
Handling of the cell therapy product is preferably performed in compliance with FACT-JACIE International Standards for cellular therapy.
Therapies and Cell Transplantation
The present invention provides a population of genome edited cells, produced or prepared according to a method of the invention for use in therapy. In some embodiments, a population of genome edited cells is used in gene therapy. In some embodiments, a population of genome edited cells may be used for hematopoietic stem cell transplantations. In some embodiments, a population of genome edited cells may be used for cancer treatments (such as for the treatment of myeloma or leukaemia). In some embodiments, a population of genome edited cells may be used for tissue repair such as the repair of tissues in skin diseases (e.g. dermis disease and epidermolysis bullosa) or retinal disease (e.g. retinitis pigmentosa and Leber's congenital amaurosis).
The term “gene therapy” as used herein refers to modifications to the genome of a cell that restore function of a defective essential gene or abolish function of a disease gene. Gene therapy may be lentiviral based or AAV based.
The use may be as part of a cell transplantation procedure, for example a haematopoietic stem cell transplantation procedure.
Haematopoietic stem cell transplantation (HSCT) is the transplantation of blood stem cells derived from the bone marrow (in this case known as bone marrow transplantation) or blood. Stem cell transplantation is a medical procedure in the fields of haematology and oncology, most often performed for people with diseases of the blood or bone marrow, or certain types of cancer.
Many recipients of HSCTs are multiple myeloma or leukaemia patients who would not benefit from prolonged treatment with, or are already resistant to, chemotherapy. Candidates for HSCTs include paediatric cases where the patient has an inborn defect such as severe combined immunodeficiency (SCID) or congenital neutropenia with defective stem cells, and also children or adults with aplastic anaemia who have lost their stem cells after birth. Other conditions treated with stem cell transplants include sickle-cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's Sarcoma, Desmoplastic small round cell tumour and Hodgkin's disease. More recently non-myeloablative, or so-called “mini transplant”, procedures have been developed that require smaller doses of preparative chemotherapy and radiation. This has allowed HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen.
In some embodiments, a population of genome edited cells prepared according to a method of the invention is administered as part of an autologous cell transplant procedure.
In other embodiments, a population of genome edited cells prepared according to a method of the invention is administered as part of an allogeneic cell transplant procedure.
The term “autologous stem cell transplant procedure” as used herein refers to a procedure in which the starting population of cells (which are then genome edited according to a method of the invention) is obtained from the same subject as that to which the population of genome edited cells is administered. Autologous transplant procedures are advantageous as they avoid problems associated with immunological incompatibility and are available to subjects irrespective of the availability of a genetically matched donor.
The term “allogeneic stem cell transplant procedure” as used herein refers to a procedure in which the starting population of cells (which are then genome edited according to a method of the invention) is obtained from a different subject as that to which the population of genome edited cells is administered. Preferably, the donor will be genetically matched to the subject to which the cells are administered to minimise the risk of immunological incompatibility.
Suitable doses of a population of genome edited cells are such as to be therapeutically and/or prophylactically effective. The dose to be administered may depend on the subject and condition to be treated, and may be readily determined by a skilled person.
Haematopoietic progenitor cells provide short term engraftment. Accordingly, gene therapy by administering transduced haematopoietic progenitor cells would provide a non-permanent effect in the subject. For example, the effect may be limited to 1-6 months following administration of the transduced haematopoietic progenitor cells.
Such haematopoietic progenitor cell gene therapy may be suited to treatment of acquired disorders, for example cancer, where time-limited expression of a (potentially toxic) anti-cancer nucleotide of interest may be sufficient to eradicate the disease.
The population of genome edited cells may be useful in the treatment of the disorders listed in WO 1998/005635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.
In addition, or in the alternative, the population of genome edited cells may be useful in the treatment of the disorders listed in WO 1998/007859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune deficiency, including infection with human immune deficiency virus; regulation of lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); anti-inflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.
In addition, or in the alternative, the population of genome edited cells may be useful in the treatment of the disorders listed in WO 1998/009985. For ease of reference, part of that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated of receptor expression in T cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal diseases, periodontal diseases or other dental diseases, orchitis or epididimo-orchitis, infertility, orchidal trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fondus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillaim-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.
In addition, or in the alternative, the population of genome edited cells may be useful in the treatment of β-thalassemia, chronic granulomatous disease, metachromatic leukodystrophy, mucopolysaccharidoses disorders and other lysosomal storage disorders.
In some embodiments, the population of genome edited cells is useful in the treatment of Severe Combined Immunodeficiency (SCID), such as X-linked SCID.
In some embodiments, the population of genome edited cells is useful in the treatment of a skin disease, such epidermolysis bullosa.
In some embodiments, the population of genome edited cells is useful in the treatment of a monogeneic disorder, such as epidermolysis bullosa and/or retinitis pigmentosa and/or Hyper-IgM (HIGM) syndrome.
In some embodiments, the population of genome edited cells is useful in the treatment of a retinal disease such as retinitis pigmentosa and/or Leber's congenital amaurosis).
In some embodiments, the population of genome edited cells is useful in the treatment of epidermolysis bullosa.
In some embodiments, the population of genome edited cells is useful in the treatment of retinitis pigmentosa.
In some embodiments, the population of genome edited cells is useful in the treatment of Leber's congenital amaurosis.
In some embodiments, the population of genome edited cells is useful in the treatment of Hyper-IgM (HIGM) syndrome.
Kit
In one aspect, there is provided a kit comprising a first component as defined herein, a second component as defined herein and a third component as defined herein and, optionally, a cell population.
The components and, optionally, the cell population may be provided in suitable containers.
The kit may also include instructions for use.
Method of Treatment
It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment; although in the context of the invention references to preventing are more commonly associated with prophylactic treatment. In some embodiments, the treatment of mammals, particularly humans, is preferred. Both human and veterinary treatments are within the scope of the invention.
The skilled person will understand that they can combine all features of the invention disclosed herein without departing from the scope of the invention as disclosed.
Administration
Although the population of genome edited cells for use in the invention can be administered alone, they will generally be administered in admixture with a pharmaceutical carrier, excipient or diluent, particularly for human therapy.
Dosage
The skilled person can readily determine an appropriate dose of the population of genome edited cells to administer to a subject without undue experimentation. Typically, a physician will determine the actual dosage which will be most suitable for an individual patient and it will depend on a variety of factors including the activity of the specific agent employed, the metabolic stability and length of action of that agent, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the individual undergoing therapy. There can of course be individual instances where higher or lower dosage ranges are merited, and such are within the scope of the invention.
Subject
A “subject” refers to either a human or non-human animal.
Examples of non-human animals include vertebrates, for example mammals, such as non-human primates (particularly higher primates), dogs, rodents (e.g. mice, rats or guinea pigs), pigs and cats. The non-human animal may be a companion animal.
Preferably, the subject is a human.
Preferred features and embodiments of the invention will now be described by way of non-limiting examples.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of chemistry, biochemistry, molecular biology, microbiology and immunology, which are within the capabilities of a person of ordinary skill in the art. Such techniques are explained in the literature. See, for example, Sambrook, J., Fritsch, E. F. and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press; Ausubel, F. M. et al. (1995 and periodic supplements) Current Protocols in Molecular Biology, Ch. 9, 13 and 16, John Wiley & Sons; Roe, B., Crabtree, J. and Kahn, A. (1996) DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; Polak, J. M. and McGee, J. O'D. (1990) In Situ Hybridization: Principles and Practice, Oxford University Press; Gait, M. J. (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; and Lilley, D. M. and Dahlberg, J. E. (1992) Methods in Enzymology: DNA Structures Part A: Synthesis and Physical Analysis of DNA, Academic Press. Each of these general texts is herein incorporated by reference.
Materials and Methods
Vectors and Nucleases
AAV6 donor templates for HDR were generated from a construct containing AAV2 inverted terminal repeats, produced by triple-transfection method and purified by ultracentrifugation on a cesium chloride gradient as previously described (1). Design of AAV-6 donor templates with homologies for AAVS1 locus (encoding for minCMV.GFP or SK.GFP reporter cassette) or targeting the intron 1 of IL2RG (encoding for IL2RG corrective cDNA followed by either a PGK.GFP reporter cassette or 2A.NGFR selector cassette) was previously reported (2). Sequences of the gRNAs for gene targeting were designed using an online CRISPR design tool (4) and selected for predicted specificity score and on target activity. Genomic sequences recognized by the gRNAs are indicated below.
Ribonucleoproteins (RNPs) were assembled by incubating at 1:1.5 molar ratio s.p.Cas9 protein (Aldevron) with synthetic cr:tracrRNA (Integrated DNA Technologies) for 10 minutes at 25° C. Electroporation enhancer (Integrated DNA Technologies) was added prior to electroporation according to manufacturer's instructions.
gRNA sequences for transactivation platforms are reported in Table 1. Sp-dCas9-VPR plasmid has been bought from Addgene (#63789) and Sp-dCas9-VP160 has been cloned from plasmid #47107 (Addgene). TALE has been cloned by Golden Gate strategy in pUC plasmid and VPR domain from plasmid #63789 fused at the C-terminus. TALE binding sites are listed in Table 2. For mRNA in vitro transcription TALE#7- or TALE#3-VPR or VP160 construct were cloned in a pVax plasmid containing a T7 promoter, β-globin 3′UTR and 64bp-polyA.
Gene Editing and Target Gene Transactivation in K562 Cell Line
The K562 cell line is a human immortalized myelogenous leukemia cell line; K562 cells are of the erythroleukemia type.
K562 cell lines were cultured in IMDM medium (GIBCO-BRL) supplemented with penicillin, streptomycin, glutamine and 10% FBS. For gene targeting experiments, 3×105 cells were electroporated (SF Cell Line 4D- Nucleofector X Kit, program EW113; Lonza) with 50 μg/ml of plasmids encoding for donor DNA template and 2.5-1.25 μM of RNPs. Cells were then expanded to perform flow cytometry and/or molecular analyses. For transactivation experiments, targeted K562 cells were electroporated with 50 μg/ml of TALE-TA or dCas9-TA plasmids and 12.5 μg/ml of U6.sgRNA plasmids, where not differently indicated.
Gene Editing and Target Gene Transactivation in Human CD34+ Cells
CD34+ cells were either freshly purified from human cord blood (CB) after obtaining informed consent and upon approval by the Ospedale San Raffaele Bioethical Committee, or purchased frozen from Lonza. CD34+ cells were edited according to a previously optimized protocol (2). Briefly, 5×105 CD34+ cells/ml were stimulated in serum-free StemSpan medium (StemCell Technologies) supplemented with penicillin, streptomycin, glutamine, 1 μM SR-1(Biovision), 50 μM UM171 (STEMCell Technologies), 10 μM PGE2 added only at the beginning of the culture (Cayman), and human early-acting cytokines (SCF 100 ng/ml, Flt3-L 100 ng/ml, TPO 20 ng/ml, and IL-6 20 ng/ml; all purchased from Peprotech). After 3 days of prestimulation, cells were washed with PBS and electroporated using P3 Primary Cell 4D-Nucleofector X Kit and program EO-100 (Lonza). Cells were electroporated with 2.5-1.25 μM of RNPs. Transduction with AAV6 was performed at a dose of 1-2×104 vg/cell 15′ after electroporation. TALE-TA mRNA was utilized where indicated at a dose of 350 μg/ml. Transactivation efficiency was measured from cultured cells in vitro 1, 2 and 7 days after electroporation by flow cytometry measuring the percentage of cells expressing the GFP marker. Gene editing efficiency was measured by digital droplet PCR analysis designing primers and probe on the junction between the vector sequence and the targeted locus and on control sequences utilized as normalizer as previously described (2).
Beads-based selection of LNGFR+ cells has been performed with MACSelect LNGFR MicroBeads, accordingly to manufacturer's instructions.
CD34+ HSPC Xenotransplantation Studies in NSG Mice
NOD-SCID-IL2Rg−/− (NSG) mice were purchased from The Jackson Laboratory and were maintained in specific-pathogen-free (SPF) conditions. The procedures involving animals were designed and performed with the approval of the Animal Care and Use Committee of the San Raffaele Hospital (IACUC #749) and communicated to the Ministry of Health and local authorities according to Italian law.
6×105CD34+ cells treated for editing and transactivation at day 5 of culture were sorted and injected intravenously into NSG mice after sub-lethal irradiation (150-180 cGy). Sample size was determined by the total number of available treated cells. Mice were attributed to each experimental group randomly. Human CD45+ cell engraftment and the presence of gene-edited cells were monitored by serial collection of blood from the mouse tail and, at the end of the experiment (>20 weeks after transplantation), bone marrow (BM) and spleen were harvested and analyzed.
Molecular Analyses
For molecular analyses, genomic DNA was isolated with DNeasy Blood & Tissue Kit or QlAamp DNA Micro Kit (QIAGEN) according to the number of cell available. Nuclease activity (IL2RG intron 1, AAVS1) was measured by mismatch-sensitive endonuclease assay by PCR-based amplification of the targeted locus followed by digestion with T7 Endonuclease I (NEB) according to the manufacturer's instructions. Digested DNA fragments were resolved and quantified by capillary electrophoresis on LabChip GX Touch HT (Perkin Elmer) according to the manufacturer's instructions.
For digital droplet PCR analysis, 5-50 ng of genomic DNA were analyzed in duplicate using the QX200 Droplet Digital PCR System (Biorad) according to the manufacturer's instructions.
For HDR ddPCR, primers and probes were designed on the junction between the vector sequence and the targeted locus and on control sequences used for normalization (human TTC5 genes). Thermal conditions for annealing and extension were adjusted for each specific application as follows: AAVS1/ Intron 1 IL2RG HDR 3′ integration junction ddPCR: 55° C. for 30 sec, 72° C. for 2 min. Primers and probes for PCR and ddPCR amplifications are shown in Table C below.
For gene expression analyses, total RNA was extracted using the RNeasy Plus Micro Kit (QIAGEN). cDNA was synthetized with SuperScript VILO IV cDNA Synthesis Kit (Invitrogen) and used for Q-PCR in a Viia7 Real-time PCR thermal cycler using TaqMan Gene Expression Assays (Applied Biosystems) mapping to IL2RG and HPRT as normalizer. The relative expression of each gene was first normalized to HPRT expression and then represented as fold change relative to the mock-treated sample.
Flow Cytometry
For immunophenotypic analyses (performed on FACSCanto II; BD Pharmingen), the antibodies listed below in Table B were used. Single stained and Fluorescence Minus One stained cells were used as controls. LIVE/DEAD Fixable Dead Cell Stain Kit (Thermo Fisher), 7-aminoactinomycin (Sigma Aldrich), were included in the sample preparation for flow cytometry according to the manufacturer's instructions to exclude dead cells from the analysis. Cell sorting was performed using MoFlo XDP Cell Sorter (Beckman Coulter) or FACSAria Fusion (BD Biosciences).
Results
The Adeno-Associated Virus Integration Site 1 (AAVS1) locus is one of the most validated genomic harbors for targeted integration of cassettes expressing a gene of interest (GOI) (Lombardo et al., 2011). Therefore, we envisaged application of the SMArT strategy disclosed herein (
To set up our ETT platforms, we designed 29 sgRNAs targeting different sequences spanning the region upstream the minCMV promoter (Table 1) and we screened them for cleavage activity in non-saturating conditions by delivering the U6.sgRNA plasmid in the clone H1. We observed that almost all the sgRNAs cut the target sequence with efficiencies above 60% (
The most widely exploited transactivating domains for target gene activation are multimeric VP16-derived proteins (such as VP64, VP128, VP160) and the tripartite transactivator VPR (VP64-p65-Rta) (Chavez et al., 2015). We fused a catalytically inactive S.p. Cas9 protein (dCas9) (harboring D10A and H840A mutations) (Jinek et al., Science 2012; 377(6096): 816-821; PMID: 2275249) with either VP160 or VPR domain and we tested the ETTs in combination with some of the previously screened sgRNAs. While ETT alone did not spuriously transactivate ΔLNGFR expression, co-delivery of the sgRNA with the ETT expressing plasmid resulted in efficient and transient transactivation with 3 out of 8 guides tested. By delivering the best performing sgRNA, we achieved up to 85% of ΔLNGFR+ cells at 48 hours after electroporation and 12- and 20-fold of ΔLNGFR cell-surface expression (measured as relative fluorescence intensity [RFI] over untreated control) with dCas9-VP160 or −VPR, respectively (
To assess whether our platform is also portable to other technologies, we fused Transcriptional Activator-Like Effector (TALE) DBDs, which recognize 9 different target sequences upstream from the minCMV promoter (Table 2), with VP160 transactivating domains and we delivered TALE-VP160 expressing plasmids in the clone H1. We found that 3 out of 9 ETTs efficiently transactivated ΔLNGFR expression and, interestingly, the most potent ETT (TALE #7) had the same binding specificity of the best performing sgRNA (
In principle, enrichment of gene-modified cells might be achieved by co-delivering the ETT together with the editing machinery (“early selection”) or by postponing ETT delivery some days after gene targeting procedure (“late selection”). In the first option, ETT binding sites must necessarily map on the genome outside the HA in order to avoid episomal donor transactivation. Therefore, we tailored the design of our vector (containing the selector cassette and the GOI cassette) to shorten the left HA and we observed only minimal impact on gene targeting efficiency when using one HA smaller than 300 bp in AAVS1 locus (
Hematopoietic stem cell (HSC) gene therapy has recently shown clear benefit for patients affected by either hematological or non-hematological inherited disorders. Targeted genome editing in HSCs would allow to improve the safety of gene therapy approaches by avoiding insertional mutagenesis and providing physiological regulation of the corrective transgene. However, the broader applicability of gene targeting-based approaches is limited by the efficiency of HDR-mediated targeted integration, especially in long-term repopulating progenitors. To investigate whether the SMArT strategy could be coupled with gene editing protocol in hematopoietic stem and progenitor cells (HSPCs), we performed gene targeting experiments in cord blood (CB)-derived CD34+ cells and we delivered by a single electroporation both AAVS1-specific nucleases (as RNP) and TALE#7 ETTs (as mRNA) (
To further increase the expression of the selector gene, the SMArT strategy could be applied in presence of translational activator, such as a modular RNA activator containing the aptamer for eukaryotic initiation factor 4G (eIF4G) that activated target mRNA translation in a 5′-UTR independent manner (Liu et al., 2018). In more detail, one or multiple binding sites for the RNA aptamer will be inserted in the corrective construct just downstream of the TSS in order to boost mRNA translation. Another possible approach to increase the expression of the selector exploits the enhancer activity of the promoter (such as EF1alpha promoter) used to drive the expression of the therapeutic gene of interest. Without wishing to be bound by theory, the presence of a strong enhancer/promoter region nearby the minimal promoter might improve transactivation efficiency on the selector gene by recruiting more transcription core factors on-site.
In parallel, we developed a similar strategy, named Selection by Means of Artificial Transactivation of Endogenous Receptors (SMArTER), which is based on transient transactivation of endogenous receptors, that can be suitable for the enrichment of cells that underwent site-specific correction of a gene whose product does not provide selective growth advantage or may not be amenable for selection (e.g. intracellular protein, not suitable for antibody-mediated recognition, etc . . . ). In these settings, expression of the selector protein depends on the transcriptional activity on the corrected gene that will be transiently transactivated by means of ETTs, thus allowing selection of the edited cells also when the corrected gene is not sufficiently expressed in target cells (
We first designed three TALE-VP160 that bind different regions of IL2RG promoter close to TATA box consensus. To test whether these TALE-based ETTs were capable of boosting gamma-chain expression, we separately electroporated TALE-VP160-expressing plasmids in K562 cell line, which basally expresses IL2RG mRNA to detectable levels (differently from HEK293T cell line). We found that only TALE#3-VP160 (referred to as T3 in the Figure) was able to induce 11-fold IL2RG overexpression, thus achieving IL2RG mRNA levels comparable to those basally measured in a male B-lymphoblastoid cell line (JY) (
In order to assess the feasibility of our selection strategy in human HSPCs, we generated a reporter for checking IL2RG promoter activity by targeting a splicing acceptor (SA).T2A.GFP cassette within the intron 1 of the gene and we co-delivered TALE#3-VP160 or TALE#3-VPR mRNA. We found no impact of transactivation activity on gene targeting efficiency but we observed a significant improvement in GFP MFI in all HSPC subpopulations in presence of TALE#3-VP160 and, especially, of TALE#3-VPR (
The SMArTER strategy could be further refined by adding to the selector gene a ligand-regulatable destabilizing domain, such as those based on the FKBP domain (Banaszynski et al., 2006) or from the from the Human Estrogen Receptor (Miyazaki et al., 2012), with the aim to avoid expression of the selector in the differentiated cells that will physiologically express the edited gene. If the SMArTER strategy is applied to correct inherited mutations that generates an absence of expression of the affected gene, and if the affected gene is a surface exposed protein, such in the case of IL2RG in SCID-X1, the SMArTER strategy could be further optimized by exploiting the corrected gene itself as selector marker. In this case, binding of ETTs on the endogenous promoter of the corrected gene will result in the overexpression of the cell surface protein, which can be used as surface marker for FACS- or magnetic beads-mediated enrichment of corrected cells.
Methods
Vectors and Nucleases
AAV6 donor templates for HDR were generated from a construct containing AAV2 inverted terminal repeats, produced by triple-transfection method and purified by ultracentrifugation on a cesium chloride gradient as previously described (Wang et al., 2015). Design of AAV6 donor templates is detailed in the Supplementary Material Section.
Sequences of the gRNAs were designed using an online CRISPR design tool (Hsu et al., 2013) and selected for predicted specificity score and on target activity. Genomic sequences recognized by the gRNAs are indicated below.
Ribonucleoproteins (RNPs) were assembled by incubating at 1:1.5 molar ratio SpCas9 protein (Aldevron) with synthetic cr:tracrRNA (Integrated DNA Technologies) for 10 minutes at 25° C. Electroporation enhancer (Integrated DNA Technologies) was added prior to electroporation according to manufacturer's instructions.
GSE56.WPRE, Ad5-E4orf6/7.WPRE and GSE56/Ad5-E4orf6/7.WPRE (which are disclosed in PCT/EP2019/066915) were synthetized with codon optimization for Homo sapiens (GeneArt™). Each construct was cloned in a pVax plasmid for mRNA in vitro transcription containing a T7 promoter, WPRE and 64bp-polyA. tTA.3′UTR was cloned in a pVax plasmid for mRNA in vitro transcription containing a T7 promoter, beta-globin 3′UTR and 64bp-polyA. The sequence of tTA mRNA is detailed in the Supplementary Material Section.
For mRNA in vitro transcription, pVax plasmid was linearized with the restriction enzyme (Spe I) and purified using phenol-chloroform. 5′-capped mRNA was in vitro transcribed using the commercial 5xMEGAscript T7 kit (Invitrogen). Synthetic RNA was purified using the RNeasy Plus Mini Kit (Qiagen) followed by HPLC column purification to remove contaminants. RNA was then concentrated using Amicon Ultra-15 (30K) (Millipore).
Gene Editing of K562 Cell Lines
The human K562 cells were maintained in Iscove's modified Dulbecco's medium (IMDM; Corning) supplemented with 10% fetal bovine serum (FBS; Euroclone), penicillin (100 IU/ml), streptomycin (100 μg/ml) and 2% glutamine. K562 cells were electroporated with 2.5-1.25 μM of RNPs. Transduction with AAV6 was performed at a dose of 1×104 vg/cell 15 minutes after electroporation.
Gene Editing of Human CD34+ Cells
CD34+ cells were purchased frozen from Lonza. CD34+ cells were edited according to a previously optimized protocol (Schiroli et al., 2017). Briefly, 5×105 CD34+ cells/ml were stimulated in serum-free StemSpan medium (StemCell Technologies) supplemented with penicillin, streptomycin, glutamine, 1 μM SR-1 (Biovision), 50 μM UM171 (STEMCell Technologies), 10 μM PGE2 added only at the beginning of the culture (Cayman), and human early-acting cytokines (SCF 100 ng/ml, Flt3-L 100 ng/ml, TPO 20 ng/ml, and IL-6 20 ng/ml; all purchased from Peprotech). After 3 days of pre-stimulation, cells were washed with PBS and electroporated using P3 Primary Cell 4D-Nucleofector X Kit and program EO-100 (Lonza). Cells were electroporated with 2.5-1.25 μM of RNPs. Transduction with AAV6 was performed at a dose of 1×104 vg/cell 15′ after electroporation. GSE56 mRNA was utilized where indicated at a dose of 150 μg/ml, Ad5-E4orf6/7 mRNA was utilized where indicated at a dose of 75 or 150 μg/ml, GSE56/Ad5-E4orf6/7 mRNA was utilized where indicated at a dose of 215 μg/ml, tTA mRNA was utilized where indicated at a dose of 150 μg/ml. Gene editing efficiency was measured from cultured cells in vitro 3 days after electroporation by flow cytometry measuring the percentage of cells expressing the GFP/truncated NGFR/CXCR4 marker or by digital droplet PCR analysis designing primers and probe on the junction between the vector sequence and the targeted locus and on control sequences utilized as normalizer.
CD34+ HSPC Xenotransplantation Studies in NSG Mice
NOD-SCID-IL2Rg−/− (NSG) mice were purchased from The Jackson Laboratory and were maintained in specific-pathogen-free (SPF) conditions. The procedures involving animals were designed and performed with the approval of the Animal Care and Use Committee of the San Raffaele Hospital (IACUC #749) and communicated to the Ministry of Health and local authorities according to Italian law.
For transplantation, 2×105CD34+ cells treated for editing at day 4.5 of culture were injected intravenously into NSG mice after sub-lethal irradiation (150-180 cGy). Sample size was determined by the total number of available treated cells. Mice were attributed to each experimental group randomly. Human CD45+ cell engraftment and the presence of gene-edited cells were monitored by serial collection of blood from the mouse tail.
Molecular Analyses
For molecular analyses, genomic DNA was isolated with DNeasy Blood & Tissue Kit or QlAamp DNA Micro Kit (QIAGEN) according to the number of cells available. For digital droplet PCR analysis, 5-50 ng of genomic DNA were analyzed using the QX200 Droplet Digital PCR System (Biorad) according to the manufacturer's instructions. For HDR ddPCR, primers and probes were designed on the junction between the vector sequence and the targeted locus and on control sequences used for normalization (human TTC5 genes). Thermal conditions for annealing and extension were adjusted as follows: 55° C. for 30 sec, 72° C. for 2 min. Primers and probes for PCR and ddPCR amplifications are shown below.
Flow Cytometry
For immunophenotypic analyses (performed on FACSCanto II; BD Pharmingen), we used the antibodies listed below. Single stained and Fluorescence Minus One-stained cells were used as controls. 7-aminoactinomycin (Sigma Aldrich) was included in the sample preparation for flow cytometry according to the manufacturer's instructions to exclude dead cells from the analysis. Cell sorting was performed using MoFlo XDP Cell Sorter (Beckman Coulter) or FACSAria Fusion (BD Biosciences).
Murine Lin-HSPC Competitive Transplantation
C57BL/6-Ly5.1 and Cd40lg−/− (CD45.2) donor mice between 6 and 10 weeks of age were euthanized by CO2 and bone marrow cells were retrieved from femurs, tibias, and humeri. HSPCs were purified by Lin- selection using the mouse Lineage Cell Depletion Kit (Miltenyi Biotec) according to the manufacturer's instructions. Cells were then cultured for 16 hours in serum-free StemSpan medium (StemCell Technologies) containing penicillin, streptomycin, glutamine, 200 ng/ml B18R Recombinant Protein (eBiovision) and a combination of mouse cytokines (20 ng/ml IL-3, 100 ng/ml SCF, 100 ng/ml Flt-3L, 50 ng/ml TPO all from Peprotech), at a concentration of 106 cells/ml. Lin- were mixed at the indicated ratios and transplanted at the indicated doses into 8-week-old lethally irradiated Cd40lg−/− mice.
Results
To assess whether transient delivery of tTA can activate selector expression, we performed targeted integration of the SMArT-D donor construct in the intron 1 of the IL2RG gene in K562 cell lines. At 14 days after targeting we observed undetectable levels of basal expression in mock-electroporated cells. On the contrary, cells electroporated 9 days after editing with different doses (0.25μg, 1 μg or 3 μg) of tTA mRNA showed efficient transactivation (
We then tested our platform in cord blood (CB)-derived CD34+ cells by co-delivering with the editing machinery tTA transactivator expressed as mRNA (
Interestingly, low dose doxycycline and delayed washout at 24 hours post-editing resulted in potent selector overexpression in the vast majority of HDR-edited cells, with no detectable transactivation in unintegrated cells upon withdrawal (
Moreover, transactivation was present in almost all the edited cells (
To demonstrate that our selection platform was portable to other relevant loci in CD34+ cells, we tested SMArT-D in the Adeno-Associated Virus Integration Site 1 (AAVS1) locus, a well-known safe harbor within the human genome, and we directly applied the protocol established in IL2RG (
We next tested the SMArT-D strategy in another clinically relevant locus, CD40LG, the causative gene of HIGM syndrome. In this case, GFP selector was replaced with truncated NGFR to demonstrate the compatibility of our strategy with clinically compliant selectors. We took advantage of our established protocol (
To improve the clinical applicability, we decided to test the same strategy replacing the marker gene (GFP or truncated NGFR) with a biological selector: in this way we can replace the in vitro selection (editing−>transient transactivation−>selection of edited cells through sorting) with an in vivo selection. In particular, we hypothesized that transient overexpression of the C-X-C chemokine receptor type 4 (CXCR4) only in HDR-edited HSPCs by SMArT-D strategy would enhance engraftment capacity of HDR-edited HSPCs conferring transient selective advantage in vivo against the NHEJ-edited or unedited counterpart. Indeed, CXCR4 is a biologically active protein involved in HSPCs migration and homing in bone marrow niche by sensitizing HSPCs to SDF1 (CXCL12) gradients (Ara et al., 2003). Moreover, CXCR4 overexpression has been shown to improve engraftment capacity of HSPCs (Kahn et al., 2004) (patent application PCT/EP2019/062666). We tested the SMArT-D strategy in the IL2RG locus both with CXCR4 wild type (WT) and mutant (WHIM) form, the latter characterized by a point mutation that increases CXCR4 stability on the membrane, possibly further prolonging CXCR4 overexpression on cell surface (Hernandez et al., 2003). For these experiments, we tested two different doses of doxycycline (400 nM and 80 nM) (
In addition, we tested whether SMArT-D strategy could be in principle combined with other strategies improving gene editing outcomes, such as those based on the use of the adenoviral protein (Ad5)-E4orf6/7, the p53 inhibitor GSE56 or their combination (PCT/EP2019/066915). Our results suggest that SMArT-D is compatible with all these platforms, without affecting transactivation efficiency (
To assess if SMArT-D manipulated HSPCs still preserve their engraftment capacity and if CXCR4-overexpressing HDR-edited cells were enriched in vivo, we transplanted 250,000 SMArT-D treated CB-derived CD34+ cells in NSG immunodeficient mice 36 h after the editing procedure, with a delay of 12 h compared with the standard procedure because of the necessity to washout doxycycline 24 h after gene editing. We had six different groups of mice:
Moreover, to possibly exploit a synergistic effect of p53 inhibition and CXCR4 overexpression we decided to test all the conditions in presence of GSE56:
Mice were monitored by performing FACS analyses and molecular assays for HDR efficiency on blood samples collected at 6, 9, 12 and 18 weeks after transplantation (
Enrichment of a pure population of corrected cells would entail transplantation of a low number of stem cells compared to bulk treated-cell transplant. Therefore, we reasoned which disease settings could benefit from reconstitution of even a limited input of functional cells. We modelled “selection-like” procedure in a mouse model of HIGM1 disease, a primary immunodeficiency due to inactivating mutation of CD40LG gene and characterized by defective IgG production in response of non-self antigens. Lethally-irradiated Cd40lg knock-out (KO) mice were transplanted with a total amount of 1,000,000 of cells of which: i) 25% Cd40lg wild-type (WT) and 75% KO or ii) 50% WT and 50% KO. To mimic a “selection-like” setting, we transplanted the same amount of WT cells, either 250,000 or 500,000, but without competition of KO cells. As controls, we transplanted 1,000,000 of KO cells or 1,000,000 of WT cells. We perform TNP/KLH vaccination 12 weeks after transplantation and we collected serum samples at 14 weeks. Mice were boosted with the TNP/KLH antigen at 15 weeks and serum samples collected (
Additional References
References Cited in Materials and Methods (Example 1)
All references cited in this specification are incorporated by reference into this specification.
The present invention is defined in the claims and the accompanying description. For convenience other aspects of the present invention are presented herein by way of numbered clauses.
1. A method for selecting genome edited cells and/or for the enrichment of genome edited cells in a population of cells comprising:
2. The method according to clause 1 wherein the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus.
3. The method according to clause 1 wherein the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates the minimal promoter when the nucleotide sequence encoding the selector is inserted into the target locus.
4. The method according to clause 1 wherein the donor reporter cassette sequentially comprises:
wherein the ETT polypeptide of the second component or the ETT polypeptide expressed by the second component activates an endogenous promoter in the target locus.
5. The method according to any one of the preceding clauses wherein the DBD is a Transcriptional Activator-Like Effector (TALE) DBD, a Zinc finger, catalytically inactive Cpf1 or catalytically inactive Cas (dCas) and wherein the TA domain is selected from the group consisting of VP16, VP64, VP128, VP160, VPR, p65, Rta, HSF1, SAM, and SunTag.
6. The method according to any one of the preceding clauses wherein the gRNA is capable of binding to one or more of the nucleotide sequences selected from the group consisting of SEQ ID NOs 1 to 31 and sequences having at least 75% identity thereto.
7. The method according to any one of the preceding clauses wherein the target locus is a safe harbour.
8. The method according to clause 7 wherein the target locus is adeno-associated virus integration site 1 (AAVS1), a common integration site (CIS) of lentiviral vectors, IL2RG, gp91phox, HBB, RAG1, CD40LG, TRAC, TRBC, STAT, PRF1, a gene encoding for a protein expressed in the skin (such as collagen, keratin, laminin, desmocolin, desmoplachine, desmoglein, placoglobin, placophylline, integrin or other proteins that are involved in desmosomes and hemidesmosomes) or another safe harbour genomic locus.
9. A kit comprising a first component, a second component and a third component as defined in any one of the preceding clauses and, optionally, a cell population.
10. A population of genome edited cells produced by the method according to any one of the preceding clauses.
11. A pharmaceutical composition comprising the population of genome edited cells according to clause 10.
12. A population of genome edited cells according to clause 10 for use in gene therapy.
13. A population of genome edited cells according to clause 10 for use in the treatment or prevention of X-linked Severe Combined Immunodeficiency (SCID-X1).
14. A population of genome edited cells according to clause 10 for use in hematopoietic stem cell transplantation (HSCT).
15. A population of genome edited cells according to clause 10 for use in tissue repair.
| Number | Date | Country | Kind |
|---|---|---|---|
| 18199952.5 | Oct 2018 | EP | regional |
This application is a U.S. National Phase of International Patent Application No. PCT/EP2019/077657, filed on Oct. 11, 2019, which claims priority to European Patent Application No. 18199952.5, filed on Oct. 11, 2018.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2019/077657 | 10/11/2019 | WO | 00 |
